



Published in final edited form as:

*Neurosci Biobehav Rev.* 2019 August ; 103: 384–398. doi:10.1016/j.neubiorev.2019.05.014.

## Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future

Nazzareno Cannella<sup>1</sup>, Massimo Ubaldi<sup>1</sup>, Alessio Masi<sup>1</sup>, Massimo Bramucci<sup>1</sup>, Marisa Roberto<sup>2</sup>, Angelo Bifone<sup>3</sup>, Roberto Ciccocioppo<sup>1</sup>

<sup>1</sup>School of Pharmacy, Pharmacology Unit, University of Camerino, 62032 Camerino, Italy

<sup>2</sup>The Scripps Research Institute, Department of Neuroscience, La Jolla, CA, USA.

<sup>3</sup>Center for Neuroscience and Cognitive Systems @UniTn, Istituto Italiano di Tecnologia, Corso Bettini 31, 38068 Rovereto, Italy

### Abstract

Alcohol Use Disorder (AUD) is a chronic disease that develops over the years. The complexity of the neurobiological processes contributing to the emergence of AUD and the neuroadaptive changes occurring during disease progression make it difficult to improve treatments. On the other hand, this complexity offers researchers the possibility to explore new targets. Over years of intense research several molecules were tested in AUD; in most cases, despite promising preclinical data, the clinical efficacy appeared insufficient to justify further development. A prototypical example is that of corticotropin releasing factor type 1 receptor (CRF1R) antagonists that showed significant effectiveness in animal models of AUD but were largely ineffective in humans. The present article attempts to analyze the most recent venues in the development of new medications in AUD with a focus on the most promising drug targets under current exploration. Moreover, we delineate the importance of using a more integrated translational framework approach to correlate preclinical findings and early clinical data to enhance the probability to validate biological targets of interest.

### Keywords

Alcoholism; Ethanol; Opioids; Brain Imaging; CRF; PET; fMRI

### Introduction

Alcohol Use Disorder (AUD) is a major leading cause of death and disability worldwide. AUD account for 44.4% of premature mortality attributable to substance abuse disorders and, within mental and drug use disorders, alcohol dependence is the fourth leading cause of years lost due to disability after depression, anxiety and drug related disorders (Whiteford et al., 2013). According to the WHO alcohol consumption caused 3.3 million deaths

worldwide in 2012 (WHO, 2014). The Center for Disease Control and Prevention (CDC) estimated that about 88000 people died for alcohol-related causes between 2006 and 2010 thus making alcohol abuse the third leading cause of preventable death after tobacco smoking and eating-related problems in US (Gonzales et al., 2014). In addition, the economic costs of AUD for the US society is estimated at about 250 billion in 2010 (Sacks et al., 2015).

Decades of neuroscience research has dramatically improved our understanding of how alcohol intake drives neuronal circuits and leads to the development of dependence after protracted use. Chronic alcohol drives long-term neuronal adaptations that reshape the cognitive and motivational organization of an individual promoting alcohol dependence. AUD is a chronic relapsing disorder characterized by a progression that starts with the experimentation of the positive reinforcing effects of the substance and ultimately leads to dependence. The latter is characterized by a loss of control over drinking and progressive emergence of compulsive drug-seeking; alcohol is consumed although the individual is aware of the adverse consequences that it causes. Once dependence is established, withdrawal from alcohol causes the emergence of aversive symptoms that promote negative emotional states characterized by dysphoria, anxiety and heightened sensitivity to stressful stimuli. In individuals suffering from this condition resumption of alcohol use leads to a relief from this negative state, thus promoting relapse to alcohol drinking. Relapse is also prompted by environmental cues associated with the positive reinforcing effects of alcohol. Drug seeking and relapse, the main clinical problems with AUD, are under the control of specific brain nuclei including hippocampus, extended amygdala, prefrontal cortex, insula and dorsal striatum (Koob and Volkow, 2010). On the other hand, the pleasurable effects of alcohol are mostly mediated by the mesolimbic dopamine pathway composed of the ventral tegmental area (VTA) and nucleus accumbens (NAc) (Koob, 1998).

Most of approved pharmacotherapies for AUD act centrally by targeting the neurobehavioral substrates that trigger the motivation for alcohol use and mediates drug reward. For example, the panopioid antagonists naltrexone and nalmefene counteract the alcohol reinforcing effects by blocking opioid receptors. Acamprosate, another approved medication, acts at least in part through modulation of the glutamate system, although the exact mechanism of action is this unclear (Spanagel et al., 2014). Differently from these molecules, the old drug disulfiram acts through peripheral mechanisms by inhibiting acetaldehyde dehydrogenase thus causing the accumulation of disliked acetaldehyde.

Unfortunately, the expanding knowledge gained on the neurobiology of AUD does not always translate into the development of new clinically efficacious treatments. Medications for AUD are still inadequate since few are available and they are moderately effective and only in some patients.

The difficulty in finding a treatment for AUD that works for everyone reside in the heterogeneity of the disorder. AUD is the result of an intricate interplay among polygenic, environmental and neurobiological components. This may explain why only a minor proportion of individuals exposed to drugs of abuse become addicted. Research has highlighted that there are specific behavioural and genetic traits that predispose an individual

to drug abuse. For example, individuals with high anxiety or highly impulsive traits are more prone to develop drug dependence (Terracciano et al., 2008; Zuckerman, 1986).

From a clinical perspective an ideal treatment for AUD should drive patients to discontinue alcohol consumption (i.e. abstinence). However, despite complete abstinence is desirable in the presence of severe liver or kidney damage, reduction of alcohol intake is also an important outcome of the therapy since it improves the quality of life and reduces social-related issues caused by alcohol (Miller et al., 1992; Rosenberg, 1993; Walitzer and Connors, 1999). A possible strategy to extend the efficacy of pharmacotherapies for AUD consists in augmenting the range of drugs available, so that clinicians would have more options to adapt the treatment strategy to the individual patient profile. A similar approach is used for depression that, as for AUD, is characterized by a diversity of responses to treatments.

The development of successful treatments requires preclinical models with high predictive validity for treatment outcome. The purpose of animal models is to replicate human conditions and several of these models have allowed, over time, to acquire significant insight into the determinants of psychiatric disorders. The advantage of animal models resides in the opportunity to control important experimental variables including environment and genetics. Moreover, animal research allows manipulations that are not possible in humans such as site-specific brain injection of a pharmacological agent or sophisticated histological and gene expression analyses of the brain that in humans are necessarily limited to post-mortem samples. In the field of alcoholism research, animal models have contributed to define the neuronal substrates involved in alcohol abuse and dependence and have demonstrated some level of predictive and translational validity for AUD.

### **Animal Models of “drinking”**

Excessive alcohol drinking is influenced by numerous factors such as availability of the substance, environment and stressful conditions associated with its use (Ciccocioppo et al., 2001; Katner et al., 1999; Le et al., 1998; Martin-Fardon et al., 2000; Martin-Fardon et al., 2010; Monti et al., 1999; Rohsenow et al., 2000). The development of alcoholism, however, is significantly linked to the presence of specific genetic traits that confer individual vulnerability to escalate alcohol use until dependence is established (Cloninger et al., 1981; Sigvardsson et al., 1996). It is estimated that genetics may account for up to 58% predisposition at the development of AUD (Kendler et al., 1997; Prescott and Kendler, 1999). Decades of alcohol research have led to the awareness that AUD is a polygenic disease, is affected by multiple external causes leading to a very heterogeneous patient populations. As a results, ideal treatments and pharmacotherapies should be tailored to the specific patient subgroups (Goldman et al., 2005; Heilig and Egli, 2006; Heilig et al., 2011). The complexity and heterogeneity of alcoholism make it difficult to find preclinical models and protocols that mimic human conditions. However, each animal models can replicate a specific aspects of human disease and thus they are unparalleled tools for drug development programs.

The preclinical models and procedures currently available have been designed to incorporate the major elements contributing to the development of the disease over time. These include the use of rat lines selectively bred for high ethanol preference and excessive drinking. Furthermore experimental animal models characterized by high alcohol drinking following chronic alcohol intoxication have been developed and validated. The use of these preclinical models, demonstrated that genetic factors are a prerequisite to develop AUD, but repeated consumption of intoxicating quantities of alcohol are fundamental in shaping the transition to AUD. Each one of the available animal models has been shown to possess some level of predictive, face and construct validity (McKinney and Bunney, 1969; Newport et al., 2002; Willner, 1984).

Successful development of naltrexone and acamprosate, two drugs clinically approved for AUD, has offered a robust proof-of-principle of the feasibility of drug development in this field (Sass et al., 1996; Volpicelli et al., 1992a). Moreover, this success has given the possibility to use these compounds to test the predictive validity of animals models. In this respect it is worth mentioning that naltrexone, a drug that reduces alcohol drinking and response to environmental cues in humans also decrease alcohol intake in several lines of rats genetically selected for excessive alcohol drinking and preference as well as in post-dependent models (Koob et al., 2003).

For instance naltrexone is efficacious in the P (Dhafer et al., 2012), the HAD (Krishnan-Sarin et al., 1998), the sP (Sabino et al., 2006), the AA (Koistinen et al., 2001) and the msP lines (Ciccocioppo et al., 2007; Perfumi et al., 2005). Remarkably, naltrexone was shown to reduce alcohol intake also in genetically heterogeneous rats as well as in monkeys (Barr et al., 2010; Kornet et al., 1991; Stromberg et al., 1998; Vallender et al., 2010).

Pharmacogenetic studies have clearly demonstrated that the efficacy of naltrexone is largely restricted to those alcoholics carrying a single nucleotide polymorphism (SNP), rs1799971, that encodes for asparagine (N) → aspartate (D) substitution in position 40 of the MOR receptor protein (see for review (Heilig et al., 2011)). Interestingly, in monkeys it was shown that responders to naltrexone carry a MOR C77G polymorphism functionally equivalent to the N40D mutation described in humans and that confer to them the sensitivity to naltrexone (Barr et al., 2010; Vallender et al., 2010).

Further evidence of the validity of preclinical rodent models is offered by acamprosate (Mann et al., 2008) that showed its efficacy on alcohol drinking in a variety of experimental paradigms (Cowen et al., 2005; Olive et al., 2002b). Interestingly, more than a decade ago it was shown that in rats a combination of acamprosate and naltrexone did not offer advantages over administration of single agents (Stromberg et al., 2001). A few years later the US COMBINE clinical trial confirmed the lack of additive effects also in humans (Anton et al., 2006). Altogether these findings provide some level of confidence for the predictive validity of animal models in alcoholism. On the other hand, data from preclinical models should be cautiously evaluated. In fact, oftentimes, contrary to what preclinical models predicted, human treatment has shown a lack of efficacy. Several examples exist, but the classical one is offered by anti-depressants belonging to a class of selective serotonin uptake blockers (SSRIs). These molecules have invariably demonstrated to possess high efficacy in attenuating alcohol drinking in laboratory animals whereas several controlled clinical trials

showed limited effectiveness in humans (Garbutt et al., 1999; Nunes and Levin, 2004). One explanation is that SSRIs elicit an anorectic effect; hence a decrease in alcohol consumption in experimental animals may represent an epiphenomenon secondary to the inhibition of consummatory behavior elicited by these agents rather than an effect on motivation for alcohol.

Voluntary drink of intoxicating doses of alcohol leads to the expression of a withdrawal syndrome once a subject, abruptly, suspend the intake. It is quite difficult to reproduce this condition in animals. However, alcohol preferring rats can spontaneously develop physical dependence if exposed to 10% alcohol over a long period of time (Kampov-Polevoy et al., 2000) and physical signs of withdrawal were induced in alcohol preferring and non-preferring rats after eight weeks of chronic voluntary alcohol consumption (Waller et al., 1982). Moreover it was observed that prolonged abstinence following a long period of ethanol administration increased anxiety levels in rats (Santucci et al., 2008). Anxiety symptoms also occur in abstinent rats after repeated cycles of alcohol intake followed by periods of withdrawal (Holter et al., 1998). As alternatives to the use of alcohol preferring rat line that voluntarily take high alcohol doses preclinical researchers have developed several models of alcohol intoxication using vapor chamber inhalation procedures or forced alcohol administration through diet or intragastric intubation (Becker, 2013; Braconi et al., 2009; Hermann et al.; Majchrowicz, 1975; Penland et al., 2001; Rimondini et al., 2002). These models have been extensively used to study neuroplasticity and maladaptive changes associated to protracted exposure to alcohol with the hope to understand the neurobiological basis of alcohol addiction (Becker, 2013). However, these models lack the voluntary component of alcohol intake which limits their construct validity. Nonetheless these models possess predictive validity as demonstrated by the effectiveness of acamprosate in reducing alcohol intake in rats in which alcohol dependence was induced via vapor inhalation (Le Magnen et al., 1987; Rimondini et al., 2008) or by the efficacy of gabapentin both in animals and humans (Mason et al., 2014; Roberto et al., 2008).

Using these genetic and post-dependent models it has been possible to shed light on negative reinforcement mechanisms responsible for excessive alcohol drinking and high relapse vulnerability in late stages of dependence (Koob, 2014)

### **Animal Models of “relapse”**

Relapse to alcohol use is mainly evoked by exposure to environmental stimuli previously associated with drug consumption. Relapse models based on environmental conditioning rely on cues that become associated with the rewarding effect of ethanol. Once re-exposed to ethanol-associated cues, the subject recalls the pleasurable effect of the drug that consequently trigger the resumption of drug use. Environmental conditioning is a long lasting phenomenon and relapse may occur even after months of abstinence (Monti et al., 2000; Sinha and Li, 2007).

Stress is another key factor in the initiation and maintenance of ethanol abuse in humans, and also plays a crucial role in relapse (Sinha et al., 2009; Sinha and Li, 2007; Sinha and O'Malley, 1999). Stress elicits mood-related symptoms (i.e., anxiety) vegetative (i.e., sleep

disturbances) and several somatic symptoms, that often drive the subject to drinking alcohol to ease these negative affective states (Breese et al., 2011).

Genetically selected alcohol preferring rats and other behavioural models of alcoholism, such as animals subjected to alcohol induced dependence and escalation of drinking, possess the capability to reproduce these complex behavioural traits. MsP rats for example can be trained to self-administer 10% alcohol or water in the presence of different discriminative environmental cues (i. e, lights, sounds our odours). If this self-administration training is followed by an extinction period during which animals are placed in the boxes without receiving the fluids or the respective cues lever pressing progressively decrease. However, seeking behavior is rapidly resumed when alcohol associated cues are presented. On the other hand, lever pressing is not enhanced following presentation of water-paired cues. Using this paradigm it was shown that genetically selected alcohol preferring rats have a more robust and persistent reinstatement of lever pressing compared to their control lines or to non selected animals (Ciccocioppo et al., 2001; Ciccocioppo et al., 2006; Maccioni et al., 2007). Similar to alcohol preferring rats, animals subjected to alcohol drinking escalation or with a history of alcohol dependence show a stronger seeking behaviour following exposure to stress or presentation of cues predictive of drug availability (Liu and Weiss, 2002a; Weiss et al., 2001).

Importantly, high relapse vulnerability in genetically selected alcohol preferring and in post-dependent rats appears to be associated to innate dysregulation of the stress system or to maladaptive reorganization of neuronal transmission. As demonstrated in several studies these changes may result in altered sensitivity to pharmacological manipulation of relapse behaviour. For instance, it has been shown that chronic ethanol exposure produces enhanced sensitivity to the inhibitory effects of D1 and D2 receptor antagonists on cue-induced drug seeking (Liu and Weiss, 2002b). A similar phenomenon was documented also for metabotropic glutamate receptors mGlu2/3 agonist LY379268 that showed higher efficacy in reducing drug-seeking in post-dependent rats compared to nondependent animals (Sidhpura et al., 2010). Conversely, naltrexone was less efficacious in preventing cue-induced drug-seeking in rats with a history of multiple alcohol intoxication and withdrawal (Ciccocioppo et al., 2003).

Genetic background and animal history also have important consequences on the sensitivity to pharmacological manipulations of stress-induced relapse. For instance, CRF1R antagonists are more efficacious in preventing stress-induced alcohol seeking in genetically selected msP rats and in animals with a history of alcohol dependence than in nondependent control animals (Gehlert et al., 2007; Hansson et al., 2006).

These findings have important implication for translational research because they suggest that different animal models and experimental paradigms may reproduce specific aspects of alcoholism or may mimic selected patient subpopulations with distinct sensitivity to pharmacological agents. The correct choice of animal models, the capacity to link them to specific patient sub-phenotypes and the ability to properly direct to them the right pharmacological agents under investigation are critical to increase the success rate of clinical trials in alcoholism.

The data available show that the reinforcing properties of alcohol are very powerful in rats genetically selected for high ethanol preference and that in these rat lines exposure to alcohol-paired cues leads to a compelling motivation for the drug. Furthermore, genetically selected preferring rats show higher sensitivity to stress compared to heterogenous non selected animals. For example, msP rats trained to alcohol self-administration show higher reinstatement of lever pressing after foot-shock stress compared to Wistar controls (Hansson et al., 2006). This innate hypersensitivity to stress can, in part, explain their high predisposition to excessive drinking and relapse vulnerability, as these behaviors may be motivated by the attempt to self-medicate from the negative affective state associated with stress sensitivity (Hansson et al., 2006). Similar results were also obtained with other alcohol preferring rat lines including AA, HAD and P that, compared to control Wistars, show an elevated propensity to relapse following stress exposure (Vengeliene et al., 2003).

Noteworthy, like genetically selected alcohol preferring rats, individuals highly sensitive to stress and/or with impaired stress-coping skills are more likely to abuse alcohol. (Bartlett and Heilig, 2011; Sinha, 2011).

In addition to operant self-administration/reinstatement paradigms, the alcohol deprivation effect (ADE) is also used to model human relapse. In this model animals are allowed to self-administer ethanol for a protracted period of time. Then they are repeatedly deprived of ethanol for a period that can last days or also months. When ethanol become available again a substantial increase in intake over the baseline reached before the deprivation is invariably observed (Heyser et al., 1997; Holter and Spanagel, 1999; McKinzie et al., 1998; Sinclair and Li, 1989; Sinclair and Senter, 1968; Vengeliene et al., 2014). Alcohol preferring rats express alcohol deprivation effect in different conditions (McKinzie et al., 1998; Rodd-Henricks et al., 2000; Sinclair and Li, 1989). It has been suggested that the increase in intake is due to an augmented motivation for alcohol, caused by craving during abstinence. This is demonstrated by the enhanced motivation for alcohol of animals subjected to ADE and tested under progressive ratio schedule of reinforcement (Spanagel and Holter, 2000). The good predictive validity of ADE was demonstrated by the efficacy of acamprosate to reduce the alcohol reinforcing effect following ethanol deprivation (Heyser et al., 1998; Holter et al., 1997). Similar results were also obtained with naltrexone that decreased alcohol intake after abstinence in a rat ADE model (Fredriksson et al., 2015; Holter and Spanagel, 1999). The ADE model embeds also important aspects of construct validity since it mimics the human condition where relapse is triggered by ingestion of alcohol following variables periods of abstinence.

## Human Laboratory Paradigm in Alcohol Research.

Human laboratory studies in alcohol addiction can be distinguished into two broad classes; the first one to model drug self-administration the second relapse. The first human laboratory study on alcohol self-administration was published by Mendelson and La Dou (Mendelson and Ladou, 1964) almost 60 years ago. Since then several additional studies have been carried out, especially over the last two decades. In self-administration experiments alcohol can be taken orally or can be delivered through intravenous (IV) infusion; each option offering advantages and disadvantages. The oral route is the more

natural and closely mimics the conditions under which subjects drink alcoholic beverages. On the other hand, following oral consumption experimental parameters can be poorly controlled due to variability across subjects in alcohol absorption, rate of drinking, time of the day, etc. Individual variability in first pass metabolism may also affect alcohol brain concentration. Intravenous infusion helps to control for several of these variables thus allowing a fine regulation of plasma/brain alcohol levels. Another advantage of IV infusion is the possibility to dissect the pharmacological actions of alcohol from the effects due to the subjective taste and/or smell response to alcohol intake. Oral and IV self-administration paradigms if used, for example, in brain imaging studies may lead to substantially different results with the latter allowing a more reliable interpretation of pharmacological effects of alcohol on the brain (Gilman et al., 2012a; Gilman et al., 2012b). Notably, IV alcohol administration has also been used to study brain responses to cues experimentally paired to alcohol, something that would have been difficult following oral administration (Kareken et al., 2012). Alcohol self-administration paradigms have been extensively used to test the effect of naltrexone under experimentally controlled conditions. Many of these studies unambiguously showed the efficacy of naltrexone to reduce alcohol drinking (see for review (Zimmermann et al., 2013)). This is one of the strongest evidences in support of the predictive validity of human laboratory paradigms thus further supporting their value in translational medicine.

Stress and environmental conditioning play a key role in shaping addictive behaviors and relapse to drug seeking (Koob and Le Moal, 1997; McLellan et al., 2000; O'Brien et al., 1998). As mentioned above exposure to environmental cues associated with the rewarding effect of ethanol can trigger the resumption of drug use (Koob and Le Moal, 1997; O'Brien et al., 1998). On the other hand stress can trigger negative somatic and affective symptoms that may drive to drug use in order to ease these negative conditions (Brown et al., 1995; Koob and Kreek, 2007; Sinha, 2001).

Over the years a massive effort has been made to model relapse behaviours in humans under experimentally controlled laboratory settings. These models largely rely on provoking relapse after exposure to alcohol associated cues or exposure to stress (Fox et al., 2012; Gilman and Hommer, 2008; Sinha, 2013; Sinha et al., 2011; Zakiniaiez et al., 2017). Occasionally, studies to evaluate how conditioning factors and stress interact with each other to facilitate relapse have also been carried out (Fox et al., 2013; Sinha et al., 2011; Thomas et al., 2011). The use of these models under laboratory controlled conditions in combination with brain imaging has allowed a tremendous advancement in the understanding of the neurobiological basis of craving and relapse (Gilman and Hommer, 2008; Sinha, 2013). Application of these approaches, together with an increased knowledge of the genetic basis and neurobiology of alcoholism has allowed researchers to distinguish endophenotypes of patients that might respond differently to pharmacological treatments. A prototypical example of this experimental approach has been published by Schacht and co-workers (Schacht et al., 2013). In this work, imaging techniques were used in a cue-reactivity study to distinguish the response to naltrexone in two subgroups of non-treatment-seeking alcohol-dependent individuals, carrying the typical A118G (Asn40Asp) single nucleotide polymorphisms in the  $\mu$ -opioid receptor (MOP) known to confer different sensitivity to MOP antagonists. Results revealed a complex three-way interaction between ventral striatum and



medial prefrontal cortex activation following exposure to cues, naltrexone treatment, and polymorphism in the MOP opioid and dopamine transporter genes (Schacht et al., 2013). Employing the MOP selective ligand [(11)C] carfentanil a PET displacement study was recently carried out to measure receptor occupancy by naltrexone in carriers of one of the two A118G (Asn40Asp) variants. A trend to a higher receptor occupancy by naltrexone was found in carriers of the G allele which may explain, at least in part, their higher sensitivity to this drug (Weerts et al., 2013). A similar study was carried to investigate how polymorphism in the gene encoding the DA transporter DAT would affect the sensitivity to the effects of the partial agonist aripiprazole. Results revealed that the compound reduced more efficaciously cue-elicited ventral striatal activation and number of drinks in subjects carrying the DAT1 9-repeat allele, that is associated with lower DAT expression, higher synaptic DA tone and greater reward-related brain activation (Schacht et al., 2018). These examples offer a clear demonstration of the importance of combining brain imaging techniques with human behavioural and pharmacological studies to predict the efficacy of medications depending on patient genotypes.

### Example of success in AUD

Valuable examples of successful translation from preclinical research to clinical development are represented by acamprosate and naltrexone, two of the three FDA approved drugs to treat AUD. A detailed analysis of the literature about these two compounds is beyond the scope of this article (for review see: (Franck and Jayaram-Lindstrom, 2013). However, it is worth mentioning that research in laboratory animals demonstrated that acamprosate attenuates alcohol consumption in rodents, mitigates some consequences of withdrawal and reduces relapse to alcohol seeking (Heyser et al., 1998). Chronic drug administration, however, has been shown to produce tolerance (Cowen et al., 2005; Lido et al., 2012; Vengeliene et al., 2010). Similarly, naltrexone reduces alcohol consumption and relapse to alcohol seeking in rats, mice and monkeys (Gilpin et al., 2008; Ji et al., 2008).

Acamprosate and naltrexone have shown some level of efficacy in humans and have been approved for clinical use. Nevertheless the Number Needed to Treat (NNT) to prevent one person to return to any drinking was quite high for both drugs (12 for acamprosate and 20 for naltrexone) meaning that only few treated patients respond to drugs (Jonas et al., 2014).

Previous studies in monkeys and in humans showed that naltrexone is not equally efficacious in all individuals treated and a link between the presence of A118G polymorphism at MOP opioid receptor locus (OPRM1) and drug efficacy was proposed (Anton et al., 2008; Barr et al., 2010; Oslin et al., 2003). These results were not confirmed by more recent studies in which the efficacy of naltrexone and GSK1521498, another opioid antagonist, appeared to be unaffected by A118G polymorphism (Oslin et al., 2015; Ziauddeen et al., 2016). Nevertheless, overall preclinical and clinical evidence offers an important demonstration of the feasibility of developing opioid antagonist-based treatments for AUD.

Other promising compounds are under current clinical investigation; one of these is baclofen, a GABA-B agonist registered for muscle spasticity. Initial studies demonstrated the efficacy of this compound in laboratory animals and in alcohol-dependent patients

(Addolorato et al., 2000a). Subsequent clinical studies demonstrated the safety of this compound in alcoholics with liver cirrhosis (Addolorato et al., 2007; Addolorato et al., 2009). The availability of nonhepatotoxic drug is very important in AUD clinical practice as chronic liver diseases are often present in alcoholics. Acamprosate is also considered a suitable drug as, due to its lack of liver metabolism it can be safely used in patients with mild hepatic insufficiency (Delgrange et al., 1992).

Since the initial studies on baclofen several other observational reports were published to demonstrate its efficacy in AUD with the drug administered in an unusually wide range of doses (from 5 to 630 mg/day) (Thompson et al., 2017). Due to still unclear results and to the difficulty of establishing the dose range at which the drug is effective and has tolerable side effects, in AUD baclofen is currently licensed in France only (Colombo et al., 2002; Soyka and Muller, 2017). An interesting new approach consists of the development of GABA-B positive allosteric modulators (PAM). Preclinical data have shown that these molecules are efficacious to lower doses compared to those needed by orthosteric GABA-B agonists like baclofen. GABA-B PAM showed efficacy in reducing alcohol intake in different animal models (Hwa et al., 2014; Liang et al., 2006; Loi et al., 2013; Maccioni et al., 2010; Maccioni et al., 2012; Orru et al., 2005) as well as reinstatement of alcohol seeking paradigms (Augier et al., 2017; Maccioni et al., 2019; Vengeliene et al., 2018).

In the attempt to identify novel treatments for AUD also various anti-epileptics have been studied. One of this molecule is gabapentin which attenuates alcohol consumption in dependent rats and attenuates anxiety levels induced by ethanol withdrawal in rats (Roberto et al., 2008; Watson et al., 1997). Initial data suggest the efficacy of gabapentin in treating alcohol abstinence in alcoholic patients in which it reduces both anxiety and episodes of heavy drinking (Mason et al., 2014; Myrick et al., 2009). Another interesting pharmacological approach is with topiramate that in mice reduced alcohol intake (Nguyen et al., 2007). Whereas in clinical trials it demonstrated efficacy in reducing drinking and in increasing the days of abstinence (Johnson et al., 2003; Johnson et al., 2007). Moreover, earlier studies demonstrated that zonisamide, another anticonvulsant, also reduce alcohol intake in rodents (Knapp et al., 2007). Later clinical studies confirmed its therapeutic potential also in humans (Arias et al., 2010; Knapp et al., 2015). As shown in Table 2 also gamma-hydroxybutyrate (GHB), also known as Sodium Oxybate (SO), displayed important positive effects on craving, attenuates drinking and protects from the expression of alcohol withdrawal (Addolorato et al., 1996; Colombo and Gessa, 2000; Gallimberti et al., 1992). However, GHB is characterised by a substantially high abuse potential that significantly limits its use (Addolorato et al., 2000b). Currently this drug is registered for the treatment of AUD in few European countries. The antiemetic serotonin-3 receptor antagonist ondansetron showed some efficacy in reducing drinking especially in early-onset alcoholics (Johnson et al., 2002; Johnson et al., 2000; Kranzler et al., 2003) and in subgroups of patients with a specific polymorphism of serotonin transporter gene (Johnson et al., 2011).

Finally, encouraging results have been reported for varenicline that shows partial agonist activity to  $\alpha 4\beta 2$  nicotinic acetylcholine receptor, approved as a smoking cessation aid. The first evidence of the efficacy of varenicline in reducing alcohol drinking was published in 2007 in the rat (Steensland et al., 2007). Since then several studies confirmed this finding in

both heavy-drinking smokers and primary alcoholics (Falk et al., 2015; McKee et al., 2009; Ray et al., 2014; Schacht et al., 2014). In a lab human study, heavy drinkers subjected to fMRI scan after chronic varenicline compared to placebo reported lower feelings of happiness and excitement following intravenous alcohol. This effect was associated with reduced BOLD signal in the ventral striatum, amygdala, and posterior insula (de Bejczy et al., 2015). In another brain imaging study, varenicline increased control over alcohol-associated thoughts and reduced the activation of the orbito-frontal cortex triggered by environmental cues (Schacht et al., 2014). These mechanisms may explain the efficacy of varenicline on alcohol drinking and support its potential effectiveness as a treatment for AUD.

## Learning from failures: the case of CRF1R antagonists

Probably the most notable failure in translational research in AUD is represented by corticotropin releasing factor type 1 receptor (CRF1R) antagonists. The corticotropin releasing factor (CRF) system, has been consolidated by more than 30 years of consistent preclinical data as one of the most promising targets to treat alcoholism. CRF1R, together with CRF2R and CRF-binding protein, are the target of this neuropeptidergic system originally characterised for its role in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis system (Bale and Vale, 2004). Subsequently a plethora of preclinical studies linked the CRF system with addiction (see for review (Koob, 2010; Ubaldi et al., 2016a). Briefly, CRF modulates both neuroendocrine stress response by activation of the HPA axis and the affective response to stress by acting on extra-hypothalamic regions (Primus et al., 1997; Sanchez et al., 1999; Van Pett et al., 2000). Through CRF1R located in the extended amygdala (Zorrilla et al., 2014), CRF regulates the withdrawal/negative effect stage of the addiction cycle (Koob and Volkow, 2010), for alcohol (Funk et al., 2006; Hansson et al., 2007; Merlo Pich et al., 1995; Olive et al., 2002a; Roberto et al., 2010; Zorrilla et al., 2001) and other drugs of abuse (Ubaldi et al., 2016a). CRF antagonists reduced anxiety induced by alcohol withdrawal in post-dependent rats (Breese et al., 2005; Gehlert et al., 2007; Knapp et al., 2004; Roberto et al., 2010; Sommer et al., 2008), decreased alcohol self-administration in rodents and prevented stress-induced reinstatement (Chu et al., 2007; Funk et al., 2007; Gehlert et al., 2007; Gilpin et al., 2008; Richardson et al., 2008; Sabino et al., 2006). Data on cocaine, nicotine, cannabinoids, opiates, and benzodiazepines confirmed the potential efficacy of CRF1R antagonism in preventing negative emotions, stress and withdrawal associated with drug abuse (Basso et al., 1999; George et al., 2007; Park et al., 2015; Rodriguez de Fonseca et al., 1997; Skelton et al., 2007; Tucci et al., 2003).

Further evidence linking the CRF1R system to drug addiction comes from genetic studies in alcohol preferring msP rats, an animal line characterized by excessive alcohol drinking, high innate anxiety and inability to engage in active responses to stress (Ayanwuyi et al., 2013; Ciccocioppo et al., 2006; Cippitelli et al., 2015; Hansson et al., 2007; Hansson et al., 2006). In msPs, these maladaptive behaviours are associated with over-expression of the corticotropin-releasing factor (CRF) system possibly triggered by two single nucleotide polymorphisms (SNPs) occurring in the promoter region (position -1836 and -2097) of the CRF1 receptor (CRF1-R) gene. Similar evidences were obtained in human genetic studies showing that CRF1R gene polymorphisms are associated with binge drinking and excessive

drinking in alcohol-dependent patients (Treutlein et al., 2006). Another study also identified gene variations at *Crh1R* locus in a caucasian population with a diagnosis of AUD (Chen et al., 2010).

This wealth of preclinical and human genetic evidences contributed to build substantial interest on CRF1R antagonists for the treatment of alcohol abuse. However, despite these promising findings, two recently developed CRF1R antagonists, pexacerfont and verucerfont, failed to yield expected clinical results (Schwandt et al., 2016). The first compound tested, pexacerfont, did not affect stress-induced alcohol craving and emotional distress, as well as BOLD-fMRI activity induced by both aversive stimuli and alcohol-associated cues (Kwako et al 2014). In addition, activation of HPA-axis induced by dexamethasone/CRF (dex/CRF) was also not affected by pexacerfont (Kwako et al., 2015). It was proposed that binding kinetics could be major determinants of the efficacy of CRF1R antagonists. In the presence of equal binding affinity, compounds with a slow receptor dissociation time constant (off-rate) should have higher efficacy (Fleck et al., 2012). Thus, attention was shifted to verucerfont a drug displaying similar binding affinity with pexacerfont but a slower off-rate constant. Results revealed attenuated brain responses to negative emotional stimuli associated with blunted HPA-axis activation and lower ACTH and cortisol release following CRF stimulation. However, despite these anti-stress like effects, verucerfont did not suppress alcohol craving or negative emotionality (Schwandt et al., 2016).

Noteworthy, lack of clinical efficacy of CRF1R antagonists was recently reported also in trials aimed at investigating the effect of these agents in post-traumatic stress disorder, major depressive disorder, generalized anxiety disorder and social anxiety disorder (Dunlop et al., 2017; Grillon et al., 2015). The reasons why the strong preclinical evidence generated over three decades of research with CRF1R antagonist did not translate into clinical efficacy is unclear.

One study on post-traumatic stress disorder reported that verucerfont is partially efficacious in a subpopulation of patients with a history of childhood abuse carrying a specific single nucleotide polymorphism (GG vs AA) at rs110402 of the *CRHR1* gene (Dunlop et al., 2017). Thus, the responsiveness of patients to CRF1R antagonism may depend on previous history of severe stress exposure and/or on their genetic background. This hypothesis is corroborated by preclinical data in msP rats showing higher efficacy of CRF1R antagonists in animals carrying two single nucleotide polymorphisms (AA v GG) in the promoter region of the *Crhr1* locus (Ayanwuyi et al., 2013; Ciccocioppo et al., 2006; Cippitelli et al., 2015; Hansson et al., 2007; Hansson et al., 2006). Notably msP rats shows also traits resembling PTSD symptoms which may contribute to their innate propensity to drink high amounts of alcohol and that could explain their high sensitivity to CRF1R blockade (Natividad et al., 2017). Other possible explanations for the failure of CRF1R antagonists in clinical studies can be related to species differences between rodents, monkeys and humans. For instance, it has been shown that brain expression and function of CRF and CRF1R may vary in species differing in parental care, maternal defense or social behavior in general (Hostetler and Ryabinin, 2013). Additionally the differences in preclinical and clinical studies may arise from divergences between human symptomology compared to animal behavior and dosage

and bioavailability of the CRF1 antagonists (Binneman et al., 2008; Dong et al., 2018; Kehne and Cain, 2010; Nielsen, 2006; Zorrilla and Koob, 2004). Despite the inconsistency between preclinical and clinical data the CRF system remains an interesting target for development of AUD medication and evidence of its role in modulating alcohol drinking continue to grow (de Guglielmo et al., 2019).

Although the experience with CRF1R antagonists may appear frustrating at first, the careful analysis of this complex system may be a key to the success of future translational drug development programs.

## Examples of emerging targets

### Nociceptin:

The neuropeptide nociceptin/orphanin FQ (N/OFQ) and its cognate receptor NOP are widely expressed in the brain. Earlier studies showed that the activation of NOP receptor by its endogenous ligand or by synthetic agonists produces a significant reduction in drinking, reduces alcohol induced conditioned place preference and attenuates reinstatement evoked by stress or cues (Ciccocioppo et al., 2004; Ciccocioppo et al., 1999; Ciccocioppo et al., 2014; Kuzmin et al., 2003; Martin-Fardon et al., 2000; Witkin et al., 2014). Subsequent investigations demonstrated that similar effect was also produced by NOP antagonism. The NOP antagonist LY2940094 decreased voluntary ethanol intake in alcohol preferring and nonpreferring rats (Rorick-Kehn et al., 2016). Moreover, NOP knockout rats self-administer significantly less alcohol than their wild-type counterpart, suggesting a facilitatory role of NOP receptors (Kallupi et al., 2017). Recent clinical data showed the translational potential of NOP modulation as LY2940094 was effective in reducing drinking in humans (Post et al., 2016). The reason why both NOP agonists and antagonists reduce the motivation for alcohol is, now, not completely clear. One recently proposed hypothesis is that NOP agonists may act through mechanisms involving desensitisation of the system (Ciccocioppo et al., 2019).

### Ghrelin:

Ghrelin is a 28-aminoacid peptide that binds and activates the growth hormone secretagogue receptor 1a (GHS-R1a) to increase appetite and food intake. Studies on rodent models showed that the blockade of GHS-R1a reduce the consumption and the motivation for alcohol (Bahi et al., 2013; Gomez et al., 2015; Gomez and Ryabinin, 2014; Jerlhag et al., 2009; Kaur and Ryabinin, 2010; Landgren et al., 2012; Suchankova et al., 2013). Accordingly, various studies demonstrated that ghrelin enhance alcohol intake when administered both centrally or systemically (Cepko et al., 2014; Jerlhag et al., 2009; Jerlhag et al., 2011). These results were replicated in humans where ghrelin administration induced alcohol craving (Leggio et al., 2014) providing an initial translational evidence.

### Orexins:

Orexin-A/Hypocretin-1 (OxA) and Orexin-B/Hypocretin-2 (OxB), also known as hypocretins, derive from a common precursor peptide and both bind to the orexin receptor 1 (OxR1) and orexin receptor 2 (OxR2), though OxR1 has higher affinity for OxA while OxR2 has equal affinity for both ligands (de Lecea et al., 1998; Sakurai et al., 1998). AUD

patients have increased blood OxA concentration during early withdrawal; peptide levels decrease after prolonged abstinence (Bayerlein et al., 2011; Ziolkowski et al., 2016). Studies in rodents showed increased OxR1 and OxR2 expression in brain areas involved in alcohol abuse (Alcaraz-Iborra et al., 2014; Barson et al., 2015). Together these findings indicate that increased orexin/hypocretin transmission may be associated with enhanced alcohol drinking. Consistently, pre-treatment with OxR1 and, in some cases OxR2, antagonists decreased alcohol and motivation for alcohol under progressive ratio contingencies consumption (Anderson et al., 2014; Brown et al., 2013; Jupp et al., 2011; Lawrence et al., 2006; Lei et al., 2016; Moorman et al., 2017; Olney et al., 2017). In addition, OxR1 antagonism reduced reinstatement of alcohol seeking elicited by alcohol-associated environmental stimuli, stress or by intracranial microinjection of neuropeptide S (Cannella et al., 2009; Jupp et al., 2011; Lawrence et al., 2006; Martin-Fardon and Weiss, 2014; Moorman et al., 2017; Richards et al., 2008; Ubaldi et al., 2016b).

## **Brain Imaging Technologies, a bridge between preclinical and clinical research.**

As already discussed, although no animal model reproduces the complexity of alcohol addiction, they offer the possibility to carry out studies under controlled environmental and genetic conditions, and thus they represent a key tool to analyze genetic and environmental components underlying alcoholism-related traits. Moreover, different animal models enable researchers to dissect out specific alcohol-related endophenotypes, such as alcohol preference, dependence, tolerance etc., and to investigate the different stages of the addiction cycle. One of the challenges in the definition of translational phenotypes is to go beyond predictive and face validity, and to relate neurobiological findings in preclinical species with specific aspects of the human syndrome, also called construct validity (McKinney and Bunney, 1969; Newport et al., 2002; Willner, 1984).

Brain imaging techniques have been widely employed to study the functional and structural organization in the human brain in search of endophenotypes that contribute to the development of alcoholism. Neuroimaging approaches enable measuring objectively the neurobiological bases of the phenotype and can be implemented in animal and human studies, thus representing a translational interface bridging clinical and preclinical research.

Among the various brain imaging techniques, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) have been broadly used to analyze psychiatric disorders such as ethanol abuse and dependence. Importantly, they can be utilized on both humans and laboratory animals.

MRI is a non-invasive imaging technique characterized by superior soft-tissue contrast, absence of ionizing radiation exposure and spatial resolution in the millimeter range (down to tens of micrometers in ultra-high-field, specialized small-animal scanners). Importantly, MRI is a very versatile technique that enables quantitative assessment of brain morphometry, segmentation of different tissue components (grey and white matter), and assessment of white matter structure and integrity through tractography-based techniques. MRI structural and morphometric investigations make it possible to test the hypothesis that the

pathophysiology of alcohol dependence is associated with quantifiable changes in global or regional neuroanatomy. Moreover, brain MRI images can be sensitized to changes in tissue perfusion and blood oxygenation levels, thus enabling non-invasive mapping of brain function, a technique dubbed functional Magnetic Resonance Imaging (fMRI). Functional MRI approaches offer new and powerful tools to study the association of specific symptoms or aspects of alcohol dependence with specific brain circuits. Through the analysis of correlations between spatially remote fMRI signals, functional and effective connectivity can be explored in the brain at rest, or under a variety of conditions or alcohol-disease-related states. fMRI methods can be also applied to investigate the acute or chronic effects of pharmacological treatment, with the aim of identifying objective markers of response to treatment in animals and patients, thus providing a potentially useful translational tool to help progress novel drugs for medication development for alcoholism from the preclinical to the clinical arena.

Positron emission tomography (PET) is a nuclear medicine imaging technique. Using specific radiopharmaceuticals, with PET is possible to analyze *in vivo* blood flow, metabolism, and receptor binding capacity in specific brain areas. Hence, PET is an imaging method characterized by very high sensitivity (it can detect molecules in picoMolar concentration) and excellent specificity. Despite its limited spatial resolution in humans, PET can also be applied to small animals using new high-resolution scanners ( $\mu$ PET) or *ex vivo* binding techniques. A miniature PE tomography has also been constructed; it is sufficiently small to be worn on the head of a fully conscious and mobile rat, thus allowing animals to be scanned without anesthesia that can be a confounding factor (Schulz et al., 2011; Schulz and Vaska, 2011).

MRI studies showed reduced grey matter volume (GMV) in the cerebral cortex (mostly frontal lobes) (Buhler and Mann, 2011; Demirakca et al., 2011; Fein et al., 2002; Rando et al., 2011), limbic areas, and cerebellum (Fein et al., 2006) of alcoholic patients. Such GMV shrinkage plays a clinically significant role in alcoholism, as it is predictive of relapse risk (Rando et al., 2011). More recently, reduced anterior insula and enlarged amygdala were associated with alcoholism (Senatorov et al., 2015). The effects of alcohol dependence on gray and white matter volume were found to affect both male and female patients (Demirakca et al., 2011). In heavy alcohol drinkers, white matter abnormalities and various functional and metabolic deficits were also reported (reviewed by (Buhler and Mann, 2011) (Gazdzinski et al., 2010; Mechtcheriakov et al., 2007; Pfefferbaum et al., 1995). Interestingly, in MRI experiments similar structural and functional alterations were described in alcohol preferring msP rats (Gozzi et al., 2013).

Functional MRI approaches have also been used to analyze spontaneous fluctuations in the brain resting state, i.e. in the absence of specific tasks or stimulation (Beckmann et al., 2005; Damoiseaux et al., 2006). Correlation patterns are thought to reflect the functional connectivity between remote brain areas, and the large-scale functional organization of the brain. Alterations in functional connectivity have been observed in several neuropsychiatric conditions (Greicius, 2008), including AUDs. Independent Component Analysis of resting state functional connectivity in AUD patients has shown overall integrity of the functional connectivity networks in patients, with reduced connectivity in certain networks, including

the default, salience and executive networks (Muller-Oehring et al., 2015). Other studies (Jansen et al., 2015; Zhu et al., 2017; Zhu et al., 2015) found an increased connectivity within prefrontal and fronto-basal networks in AUD patients or young binge drinkers (Correas et al., 2016). Whether these discrepancies reflect methodological differences in the assessment of functional connectivity, or specific traits or states of the patient subgroups enrolled in different studies is unclear.

[18F]FDG-PET studies reported reduced metabolism in frontal-parietal, orbitofrontal cortex and striatal areas in active and abstinent alcohol-abusers (Gilman et al., 1990; Volkow et al., 1992; Volkow et al., 1994; Volkow et al., 1997; Wang et al., 2000).

Using [11C]raclopride as a radiotracer, blunted amphetamine-induced dopamine release was observed in the nucleus accumbens of alcohol dependent subjects compared with healthy subjects (Martinez et al., 2004). In human alcoholics and post-dependent rats were also reported variations from a hypo- to a hyper-dopaminergic state during three weeks of alcohol abstinence suggesting a composite regulation of brain DA mechanisms that depends by time and state (Hirth et al., 2016). Altogether these results suggest that, following an initially exaggerated dopamine response to ethanol, the dopamine tone in the ventral striatum may fluctuate with time, possibly resulting in a blunted response associated with emergence of craving and relapse. Interestingly, a very similar effect was observed in cocaine addicts (Martinez et al., 2007), thus indicating convergent effects of different drugs of abuse on the brain reward system.

The role of the brain stress systems in sustained alcohol use and relapse has been emphasized (George et al., 2008). The involvement of the neurokinine 1 receptor, a mediator of behavioral stress responses, was shown in an fMRI study in abstinent alcoholics exposed to negative and positive stimuli from the International Affective Picture System (IAPS) and pictures of alcoholic or neutral beverages (George et al., 2008). Alcoholics patients displayed excessive brain responses to images correlated with negative situations while the brain responses were reduced when they were confronted with images of positive values. Treatment with LY686017, a potent and selective Nk1R antagonist, reversed this effect in several brain regions. In particular LY686017 reduced the activation of the insula, an area implicated in craving and in the maintenance of addictive behaviors (George et al., 2008).

Recent neuroimaging studies indicated that individuals with high vulnerability to ethanol abuse had reduced cortical and thalamic GMV (Benegal et al., 2007) and an altered sensitivity of the reward circuitry (Acheson et al., 2009; Andrews et al., 2011; Kareken et al., 2010). Interestingly, these two conditions were observed also in alcoholic patients during withdrawal. These preliminary findings suggest that structural and functional abnormalities could be derived from chronic alcohol use but they may also represent innate feature conferring propensity toward ethanol addiction.

The role played by innate brain abnormalities in alcohol abuse vulnerability have been studied in the msP rat, using multimodal neuroimaging modalities (Gozzi et al., 2013). As previously described the msP rat line closely mimics several fundamental aspects of alcoholism in humans, such binge drinking behavior, negative affective states associated



with alcohol use, hypersensitivity to stress, anxiety and depression (Ciccocioppo et al., 2006; Hansson et al., 2006). Interestingly, these animals appear to have an up-regulated CRF1R system, which may determine the poor ability to cope with stress, like human subjects that drink ethanol as an anxiety-relieving strategy.

In accordance with observations in alcoholics during the withdrawal phase and in individuals at high-risk for ethanol abuse, structural and functional MRI in msP rats showed reduced GMV in the thalamus, ventral tegmental area, insular and cingulate cortex. Also, msP rats highlighted significantly reduced basal Cerebral Blood Volume (bCBV), a marker of resting brain function, in various brain areas. These effects were observed in the cingulate cortex, striatum, thalamus, hypothalamus, ventral hippocampus and corpus callosum (Gozzi et al., 2013). Foci of reduced bCBV were present in the central nucleus of the amygdala, shell of NAc and bed nucleus of the stria terminalis (Gozzi et al., 2013). Interestingly, the striatum, the thalamo-cortical circuits and NAc showed a reduced metabolism. Previous studies on alcohol demonstrated that the functional reactivity of these brain areas is altered in task- or cue-based fMRI activation (Kareken et al., 2004; Vollstadt-Klein et al., 2010). These findings show that the brain of alcohol preferring msP rats exhibit abnormalities similar of those observed in alcoholics. The animals in this study were analyzed in an alcohol-naïve state suggesting that some of the morphological and functional features observed in alcoholics might be present before alcohol exposure and be a factor predisposing to AUD. Whether predisposition to alcohol abuse confers vulnerability to addiction to other substances, as suggested by other forms of drug abuse often observed in alcoholics, remains an open question. To this end, a recent study in msP rats applied a combination of behavioral, neurochemistry and functional imaging techniques to study responses to psychostimulants (Bifone et al., 2018). Pharmacological MRI revealed increased functional reactivity to d-amphetamine in the extended amygdala of msPs, associated with increased extracellular levels of dopamine in the shell of NAc, and with increased propensity to escalate drug use. These results suggest neurobiological and neurochemical substrates involved in the transition from drug use to addiction independently from the drug used. Moreover, it suggests that increased functional responses to stimulants in the extended amygdala may predict individual vulnerability to transitioning to addiction.

With the increasing availability of diagnostic tools and the improvement of their mining capacity, it will be possible to acquire several data modalities for each subject. A multimodal analysis including not only different MRI acquisition paradigms or PET, but also genetic and behavioural data, would allow a comprehensive characterization of the subject, improving the strength of diagnosis and evaluation of treatment outcomes respect to each single modality taken on its own. This approach was recently tested in a longitudinal preclinical MRI study. MsP rats were subjected to voluntary alcohol drinking and then treated with naltrexone during abstinence. Multimodal MRI acquisition were repeated at naïve, intoxicated, and after naltrexone treatment stages. Data showed that it is possible to differentiate multimodal fingerprints of naïve and intoxicated stages and that naltrexone treatment reverted the fingerprint of intoxicated rats back toward the naïve stage (Cosa et al., 2017). This seminal work indicate that a multimodal approach could help detect biomarkers characterizing the transition into an addictive state that could also be integrated in the evaluation of treatment outcome and be helpful in the development of novel drugs.

## Conclusions and Remarks

Alcohol abuse and dependence are serious disabling conditions that have a dramatic impact on our society and public health. Neurobiological processes involved in the development of AUD are the result of complex interactions between genetic and environmental determinants. One of the major results in drug development programs for AUD was the approval of naltrexone for clinical use. This opioid antagonist is now considered one of the most important pharmacotherapeutic options in the clinical care of alcoholics. Over the years, in addition to naltrexone, other molecules, such as acamprosate and nalmefene have been approved. Other molecules like gabapentin, baclofen and varenicline, now in the clinic for a different use, are under investigation for future authorization in AUD. Additional compounds targeting a number of other mechanisms (i.e., nociceptin, orexin, ghrelin, dopamine, etc.) are at an earlier stage of development. For some of these compounds preclinical findings are strikingly encouraging. Thus, the hope is to have the possibility to test them in AUD patients soon. Of note the mechanisms used by classical drugs like nalmefene and naltrexone consist of attenuating the rewarding and the reinforcing effect of alcohol. To some extent similar mechanism is used by disulfiram that act as a deterrent by blocking alcohol metabolism. Consistently blockade of orexin, ghrelin or stimulation/blockade of nociceptin receptor may also lead to reduction of alcohol reward. On the contrary molecules like varenicline and baclofen may partially substitute for alcohol. The successful development of effective medications in AUD provides a proof-of-concept for the feasibility of treating alcoholism with pharmacological agents. On the other hand, the efficacy of currently available medications is not satisfactory and successful development of more efficacious and safer drugs is highly desirable. To enhance the possibility of successfully moving new drugs from bench to bedside it is crucial to establish appropriate strategies of drug development. Learning from negative experiences like the one made with CRF1R antagonists is also of fundamental importance; preclinical data, although promising, does not always predict the clinical efficacy of a new treatment. As highlighted above, several factors may account for this lack of success. Availability of validated preclinical models and the correct use of human laboratory paradigms with appropriate markers able to predict clinical efficacy are two important conditions to reduce the risk of failure. Whereas systematic use of brain imaging methods can help to interpret findings in preclinical models and to translate them to the human level.

## Acknowledgements

This work was supported by the National Institutes of Health, grant RO1 AA017447 (MR and RC) and RO1 AA014351 (FW and RC) from the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

## References

- Acheson A, Robinson JL, Glahn DC, Lovallo WR, Fox PT, 2009 Differential activation of the anterior cingulate cortex and caudate nucleus during a gambling simulation in persons with a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project. *Drug Alcohol Depend* 100, 17–23. [PubMed: 19026496]
- Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G, 2000a Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. *Alcohol Clin Exp Res* 24, 67–71. [PubMed: 10656195]

- Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G, 2002 Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. *Alcohol and Alcoholism* 37, 504–508. [PubMed: 12217947]
- Addolorato G, Caputo F, Capristo E, Stefanini GF, Gasbarrini G, 2000b Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. *Alcohol* 20, 217–222. [PubMed: 10869862]
- Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, Bernardi M, Gasbarrini G, 1996 An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. *GHB Study Group. Alcohol Alcohol* 31, 341–345.
- Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G, 2007 Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. *Lancet* 370, 1915–1922. [PubMed: 18068515]
- Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L, 2009 Understanding and treating patients with alcoholic cirrhosis: an update. *Alcohol Clin Exp Res* 33, 1136–1144. [PubMed: 19389182]
- Alcaraz-Iborra M, Carvajal F, Lerma-Cabrera JM, Valor LM, Cubero I, 2014 Binge-like consumption of caloric and non-caloric palatable substances in ad libitum-fed C57BL/6J mice: pharmacological and molecular evidence of orexin involvement. *Behav Brain Res* 272, 93–99. [PubMed: 24983661]
- Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM, 2014 Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. *Front Neurosci* 8, 33. [PubMed: 24616657]
- Andrews MM, Meda SA, Thomas AD, Potenza MN, Krystal JH, Worhunsky P, Stevens MC, O'Malley S, Book GA, Reynolds B, Pearson GD, 2011 Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. *Biol Psychiatry* 69, 675–683. [PubMed: 21126735]
- Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, Group CSR, 2006 Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. *JAMA* 295, 2003–2017. [PubMed: 16670409]
- Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D, 2008 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. *Arch Gen Psychiatry* 65, 135–144. [PubMed: 18250251]
- Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR, 2010 Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. *J Clin Psychopharmacol* 30, 318–322. [PubMed: 20473070]
- Augier E, Dulman RS, Damadzic R, Pilling A, Hamilton JP, Heilig M, 2017 The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats. *Neuropsychopharmacology* 42, 1789–1799. [PubMed: 28294133]
- Ayanwuyi LO, Carvajal F, Lerma-Cabrera JM, Domi E, Bjork K, Ubaldi M, Heilig M, Roberto M, Ciccocioppo R, Cippitelli A, 2013 Role of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of marchigian sardinian alcohol-preferring rats. *Front Psychiatry* 4, 23. [PubMed: 23630503]
- Ayanwuyi LO, Stopponi S, Ubaldi M, Cippitelli A, Nasuti C, Damadzic R, Heilig M, Schank J, Cheng K, Rice KC, Ciccocioppo R, 2015 Neurokinin 1 receptor blockade in the medial amygdala attenuates alcohol drinking in rats with innate anxiety but not in Wistar rats. *Br J Pharmacol* 172, 5136–5146. [PubMed: 26275374]
- Bahi A, Tolle V, Fehrentz JA, Brunel L, Martinez J, Tomasetto CL, Karam SM, 2013 Ghrelin knockout mice show decreased voluntary alcohol consumption and reduced ethanol-induced conditioned place preference. *Peptides* 43, 48–55. [PubMed: 23428971]
- Bale TL, Vale WW, 2004 CRF and CRF receptors: role in stress responsivity and other behaviors. *Annu Rev Pharmacol Toxicol* 44, 525–557. [PubMed: 14744257]

- Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M, 2010 Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. *Biol Psychiatry* 67, 78–80. [PubMed: 19748082]
- Barson JR, Ho HT, Leibowitz SF, 2015 Anterior thalamic paraventricular nucleus is involved in intermittent access ethanol drinking: role of orexin receptor 2. *Addict Biol* 20, 469–481. [PubMed: 24712379]
- Bartlett S, Heilig M, 2011 Translational Approaches to Medication Development. *Curr Top Behav Neurosci*.
- Basso AM, Spina M, Rivier J, Vale W, Koob GF, 1999 Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like” effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. *Psychopharmacology (Berl)* 145, 21–30. [PubMed: 10445369]
- Bayerlein K, Kraus T, Leinonen I, Pilniok D, Rotter A, Hofner B, Schwitulla J, Sperling W, Kornhuber J, Biermann T, 2011 Orexin A expression and promoter methylation in patients with alcohol dependence comparing acute and protracted withdrawal. *Alcohol* 45, 541–547. [PubMed: 21621370]
- Becker HC, 2013 Animal models of excessive alcohol consumption in rodents. *Curr Top Behav Neurosci* 13, 355–377. [PubMed: 22371267]
- Beckmann CF, DeLuca M, Devlin JT, Smith SM, 2005 Investigations into resting-state connectivity using independent component analysis. *Philos Trans R Soc Lond B Biol Sci* 360, 1001–1013. [PubMed: 16087444]
- Benegal V, Antony G, Venkatasubramanian G, Jayakumar PN, 2007 Gray matter volume abnormalities and externalizing symptoms in subjects at high risk for alcohol dependence. *Addict Biol* 12, 122–132. [PubMed: 17407506]
- Berizzi AE, Perry CJ, Shackelford DM, Lindsley CW, Jones CK, Chen NA, Sexton PM, Christopoulos A, Langmead CJ, Lawrence AJ, 2018 Muscarinic M5 receptors modulate ethanol seeking in rats. *Neuropsychopharmacology* 43, 1510–1517. [PubMed: 29483658]
- Bifone A, Gozzi A, Cippitelli A, Matzeu A, Domi E, Li H, Scuppa G, Cannella N, Ubaldi M, Weiss F, Ciccocioppo R, 2018 pHMRI, neurochemical and behavioral responses to psychostimulants distinguishing genetically selected alcohol-preferring from genetically heterogenous rats. *Addiction Biology* In Press.
- Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T, 2008 A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. *Am J Psychiatry* 165, 617–620. [PubMed: 18413705]
- Blednov YA, Benavidez JM, Black M, Ferguson LB, Schoenhard GL, Goate AM, Edenberg HJ, Wetherill L, Hesselbrock V, Foroud T, Harris RA, 2015 Peroxisome proliferator-activated receptors alpha and gamma are linked with alcohol consumption in mice and withdrawal and dependence in humans. *Alcohol Clin Exp Res* 39, 136–145. [PubMed: 25516156]
- Bouza C, Angeles M, Munoz A, Amate JM, 2004 Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. *Addiction* 99, 811–828. [PubMed: 15200577]
- Braconi S, Sidhpura N, Aujla H, Martin-Fardon R, Weiss F, Ciccocioppo R, 2009 Revisiting Intragastric Ethanol Intubation as a Dependence Induction Method for Studies of Ethanol Reward and Motivation in Rats. *Alcohol Clin Exp Res*.
- Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Le DA, O’Dell LE, Overstreet DH, Roberts AJ, Sinha R, Valdez GR, Weiss F, 2005 Stress enhancement of craving during sobriety: a risk for relapse. *Alcohol Clin Exp Res* 29, 185–195. [PubMed: 15714042]
- Breese GR, Sinha R, Heilig M, 2011 Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. *Pharmacol Ther* 129, 149–171. [PubMed: 20951730]
- Brown RM, Khoo SY, Lawrence AJ, 2013 Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. *Int J Neuropsychopharmacol* 16, 2067–2079. [PubMed: 23601187]

- Brown SA, Vik PW, Patterson TL, Grant I, Schuckit MA, 1995 Stress, vulnerability and adult alcohol relapse. *J Stud Alcohol* 56, 538–545. [PubMed: 7475034]
- Buhler M, Mann K, 2011 Alcohol and the human brain: a systematic review of different neuroimaging methods. *Alcohol Clin Exp Res* 35, 1771–1793. [PubMed: 21777260]
- Cannella N, Economidou D, Kallupi M, Stopponi S, Heilig M, Massi M, Ciccocioppo R, 2009 Persistent increase of alcohol-seeking evoked by neuropeptide S: an effect mediated by the hypothalamic hypocretin system. *Neuropsychopharmacology* 34, 2125–2134. [PubMed: 19322167]
- Cannella N, Kallupi M, Li HW, Stopponi S, Cifani C, Ciccocioppo R, Ubaldi M, 2016 Neuropeptide S differently modulates alcohol-related behaviors in alcohol-preferring and non-preferring rats. *Psychopharmacology (Berl)* 233, 2915–2924. [PubMed: 27235017]
- Cepko LC, Selva JA, Merfeld EB, Fimmel AI, Goldberg SA, Currie PJ, 2014 Ghrelin alters the stimulatory effect of cocaine on ethanol intake following mesolimbic or systemic administration. *Neuropharmacology* 85, 224–231. [PubMed: 24880084]
- Chen AC, Manz N, Tang Y, Rangaswamy M, Almasy L, Kuperman S, Nurnberger J Jr., O'Connor SJ, Edenberg HJ, Schuckit MA, Tischfield J, Foroud T, Bierut LJ, Rohrbaugh J, Rice JP, Goate A, Hesselbrock V, Porjesz B, 2010 Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. *Alcohol Clin Exp Res* 34, 988–996. [PubMed: 20374216]
- Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ, 2007 Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. *Pharmacology, Biochemistry and Behavior* 86, 813–821.
- Ciccocioppo R, Angeletti S, Weiss F, 2001 Long-lasting resistance to extinction of response reinstatement induced by ethanol-related stimuli: role of genetic ethanol preference. *Alcohol Clin Exp Res* 25, 1414–1419. [PubMed: 11696659]
- Ciccocioppo R, Borruto AM, Domi A, Teshima K, Cannella N, Weiss F, 2019 NOP-Related Mechanisms in Substance Use Disorders. *Handb Exp Pharmacol*.
- Ciccocioppo R, Economidou D, Cippitelli A, Cucculelli M, Ubaldi M, Soverchia L, Lourdasamy A, Massi M, 2006 Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. *Addict Biol* 11, 339–355. [PubMed: 16961763]
- Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, Massi M, 2004 Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. *Psychopharmacology* 172, 170–178. [PubMed: 14624331]
- Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M, 2007 Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. *Biol Psychiatry* 61, 4–12. [PubMed: 16533497]
- Ciccocioppo R, Lin D, Martin-Fardon R, Weiss F, 2003 Reinstatement of ethanol-seeking behavior by drug cues following single versus multiple ethanol intoxication in the rat: effects of naltrexone. *Psychopharmacology* 168, 208–215. [PubMed: 12664190]
- Ciccocioppo R, Panocka I, Polidori C, Regoli D, Massi M, 1999 Effect of nociceptin on alcohol intake in alcohol-preferring rats. *Psychopharmacology* 141, 220–224. [PubMed: 9952048]
- Ciccocioppo R, Stopponi S, Economidou D, Kuriyama M, Kinoshita H, Heilig M, Roberto M, Weiss F, Teshima K, 2014 Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat. *Neuropsychopharmacology* 39, 2601–2610. [PubMed: 24863033]
- Cippitelli A, Ayanwuyi LO, Barbier E, Domi E, Lerma-Cabrera JM, Carvajal F, Scuppa G, Li H, Ubaldi M, Heilig M, Roberto M, Ciccocioppo R, 2015 Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats. *Psychopharmacology (Berl)* 232, 1083–1093. [PubMed: 25260340]
- Cloninger CR, Bohman M, Sigvardsson S, 1981 Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. *Arch Gen Psychiatry* 38, 861–868. [PubMed: 7259422]

- Colombo G, Gessa GL, 2000 Gamma-hydroxybutyric acid in alcohol preference, dependence and withdrawal. *Addict Biol* 5, 389–403. [PubMed: 20575856]
- Colombo G, Serra S, Brunetti G, Atzori G, Pani M, Vacca G, Addolorato G, Froestl W, Carai MA, Gessa GL, 2002 The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. *Alcohol Alcohol* 37, 499–503. [PubMed: 12217946]
- Correas A, Cuesta P, Lopez-Caneda E, Rodriguez Holguin S, Garcia-Moreno LM, Pineda-Pardo JA, Cadaveira F, Maestu F, 2016 Functional and structural brain connectivity of young binge drinkers: a follow-up study. *Sci Rep* 6, 31293. [PubMed: 27506835]
- Cosa A, Moreno A, Pacheco-Torres J, Ciccocioppo R, Hyytia P, Sommer WH, Moratal D, Canals S, 2017 Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain. *Addict Biol* 22, 1459–1472. [PubMed: 27273582]
- Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ, 2005 The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. *Addict Biol* 10, 233–242. [PubMed: 16109584]
- Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF, 2006 Consistent resting-state networks across healthy subjects. *Proc Natl Acad Sci U S A* 103, 13848–13853. [PubMed: 16945915]
- de Bejczy A, Lof E, Walther L, Guterstam J, Hammarberg A, Asanovska G, Franck J, Isaksson A, Soderpalm B, 2015 Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. *Alcohol Clin Exp Res* 39, 2189–2199. [PubMed: 26414337]
- de Guglielmo G, Kallupi M, Pomrenze MB, Crawford E, Simpson S, Schweitzer P, Koob GF, Messing RO, George O, 2019 Inactivation of a CRF-dependent amygdalofugal pathway reverses addiction-like behaviors in alcohol-dependent rats. *Nat Commun* 10, 1238. [PubMed: 30886240]
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG, 1998 The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci U S A* 95, 322–327. [PubMed: 9419374]
- Delgrange T, Khater J, Capron D, Duron B, Capron JP, 1992 [Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis]. *Gastroenterol Clin Biol* 16, 687–691. [PubMed: 1426825]
- Demirakca T, Ende G, Kammerer N, Welzel-Marquez H, Hermann D, Heinz A, Mann K, 2011 Effects of alcoholism and continued abstinence on brain volumes in both genders. *Alcohol Clin Exp Res* 35, 1678–1685. [PubMed: 21599718]
- Dhafer R, Toalston JE, Hauser SR, Bell RL, McKinzie DL, McBride WJ, Rodd ZA, 2012 Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats. *Alcohol* 46, 17–27. [PubMed: 21962974]
- Dong H, Keegan JM, Hong E, Gallardo C, Montalvo-Ortiz J, Wang B, Rice KC, Csernansky J, 2018 Corticotrophin releasing factor receptor 1 antagonists prevent chronic stress-induced behavioral changes and synapse loss in aged rats. *Psychoneuroendocrinology* 90, 92–101. [PubMed: 29477954]
- Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS, 2017 Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. *Biol Psychiatry* 82, 866–874. [PubMed: 28793974]
- Economidou D, Cippitelli A, Stopponi S, Braconi S, Clementi S, Ubaldi M, Martin-Fardon R, Weiss F, Massi M, Ciccocioppo R, 2011 Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat. *Alcoholism, Clinical and Experimental Research* 35, 747–755.
- Falk DE, Castle IJ, Ryan M, Fertig J, Litten RZ, 2015 Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis. *J Addict Med* 9, 296–303. [PubMed: 26083958]

- Fein G, Di Sclafani V, Cardenas VA, Goldmann H, Tolou-Shams M, Meyerhoff DJ, 2002 Cortical gray matter loss in treatment-naive alcohol dependent individuals. *Alcohol Clin Exp Res* 26, 558–564. [PubMed: 11981133]
- Fein G, Landman B, Tran H, McGillivray S, Finn P, Barakos J, Moon K, 2006 Brain atrophy in long-term abstinent alcoholics who demonstrate impairment on a simulated gambling task. *Neuroimage* 32, 1465–1471. [PubMed: 16872844]
- Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE, 2012 Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. *J Pharmacol Exp Ther* 341, 518–531. [PubMed: 22357972]
- Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R, 2012 Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. *Alcohol Clin Exp Res* 36, 351–360. [PubMed: 21919922]
- Fox HC, Tuit KL, Sinha R, 2013 Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine. *Hum Psychopharmacol* 28, 40–53. [PubMed: 23280514]
- Franck J, Jayaram-Lindstrom N, 2013 Pharmacotherapy for alcohol dependence: status of current treatments. *Curr Opin Neurobiol* 23, 692–699. [PubMed: 23810221]
- Fredriksson I, Jayaram-Lindstrom N, Wirf M, Nylander E, Nystrom E, Jardemark K, Steensland P, 2015 Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. *Neuropsychopharmacology* 40, 1130–1140. [PubMed: 25359257]
- Funk CK, O'Dell LE, Crawford EF, Koob GF, 2006 Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. *J Neurosci* 26, 11324–11332. [PubMed: 17079660]
- Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF, 2007 Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. *Biol Psychiatry* 61, 78–86. [PubMed: 16876134]
- Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL, 1992 gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. *Alcohol Clin Exp Res* 16, 673–676. [PubMed: 1326902]
- Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT, 1999 Pharmacological treatment of alcohol dependence: a review of the evidence. *JAMA* 281, 1318–1325. [PubMed: 10208148]
- Gazdzinski S, Durazzo TC, Mon A, Yeh PH, Meyerhoff DJ, 2010 Cerebral white matter recovery in abstinent alcoholics--a multimodality magnetic resonance study. *Brain* 133, 1043–1053. [PubMed: 20133395]
- Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M, 2007 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. *J Neurosci* 27, 2718–2726. [PubMed: 17344409]
- George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M, 2008 Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. *Science* 319, 1536–1539. [PubMed: 18276852]
- George O, Ghosland S, Azar MR, Cottone P, Zorrilla EP, Parsons LH, O'Dell LE, Richardson HN, Koob GF, 2007 CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. *Proc Natl Acad Sci U S A* 104, 17198–17203. [PubMed: 17921249]
- Gilman JM, Hommer DW, 2008 Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. *Addict Biol* 13, 423–434. [PubMed: 18507736]
- Gilman JM, Ramchandani VA, Crouss T, Hommer DW, 2012a Subjective and neural responses to intravenous alcohol in young adults with light and heavy drinking patterns. *Neuropsychopharmacology* 37, 467–477. [PubMed: 21956438]
- Gilman JM, Smith AR, Ramchandani VA, Momenan R, Hommer DW, 2012b The effect of intravenous alcohol on the neural correlates of risky decision making in healthy social drinkers. *Addict Biol* 17, 465–478. [PubMed: 21995446]

- Gilman S, Adams K, Koeppe RA, Berent S, Kluin KJ, Modell JG, Kroll P, Brunberg JA, 1990 Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. *Ann Neurol* 28, 775–785. [PubMed: 2285264]
- Gilpin NW, Richardson HN, Koob GF, 2008 Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. *Alcoholism, Clinical and Experimental Research* 32, 1535–1542.
- Goldman D, Oroszi G, Ducci F, 2005 The genetics of addictions: uncovering the genes. *Nat Rev Genet* 6, 521–532. [PubMed: 15995696]
- Gomez JL, Cunningham CL, Finn DA, Young EA, Helpenstell LK, Schuette LM, Fidler TL, Kosten TA, Ryabinin AE, 2015 Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence. *Neuropharmacology* 97, 182–193. [PubMed: 26051399]
- Gomez JL, Ryabinin AE, 2014 The effects of ghrelin antagonists [D-Lys(3)]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL/6J mice. *Alcohol Clin Exp Res* 38, 2436–2444. [PubMed: 25257292]
- Gonzales K, Roeber J, Kanny D, Tran A, Saiki C, Johnson H, Yeoman K, Safranek T, Creppage K, Lepp A, Miller T, Tarkhashvili N, Lynch KE, Watson JR, Henderson D, Christenson M, Geiger SD, Centers for Disease, C., Prevention, 2014 Alcohol-attributable deaths and years of potential life lost—11 States, 2006–2010. *MMWR Morb Mortal Wkly Rep* 63, 213–216. [PubMed: 24622285]
- Gozzi A, Agosta F, Massi M, Ciccocioppo R, Bifone A, 2013 Reduced limbic metabolism and fronto-cortical volume in rats vulnerable to alcohol addiction. *Neuroimage* 69, 112–119. [PubMed: 23261637]
- Greicius M, 2008 Resting-state functional connectivity in neuropsychiatric disorders. *Curr Opin Neurol* 21, 424–430. [PubMed: 18607202]
- Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M, 2015 The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. *Neuropsychopharmacology* 40, 1064–1071. [PubMed: 25430779]
- Gual A, He Y, Torup L, van den Brink W, Mann K, Group ES, 2013 A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. *Eur Neuropsychopharmacol* 23, 1432–1442. [PubMed: 23562264]
- Hansson AC, Cippitelli A, Sommer WH, Ciccocioppo R, Heilig M, 2007 Region-specific down-regulation of *Crhr1* gene expression in alcohol-preferring msP rats following ad lib access to alcohol. *Addict Biol* 12, 30–34. [PubMed: 17407495]
- Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Bjork K, Soverchia L, Terasmaa A, Massi M, Heilig M, Ciccocioppo R, 2006 Variation at the rat *Crhr1* locus and sensitivity to relapse into alcohol seeking induced by environmental stress. *Proc Natl Acad Sci U S A* 103, 15236–15241. [PubMed: 17015825]
- Heilig M, Egli M, 2006 Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. *Pharmacol Ther* 111, 855–876. [PubMed: 16545872]
- Heilig M, Goldman D, Berrettini W, O'Brien CP, 2011 Pharmacogenetic approaches to the treatment of alcohol addiction. *Nat Rev Neurosci* 12, 670–684. [PubMed: 22011682]
- Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, Perreau-Lenz S, Hansson AC, Krumm B, Kiefer F, Spanagel R, Mann K, Ende G, Sommer WH, Translational Magnetic Resonance Spectroscopy Reveals Excessive Central Glutamate Levels During Alcohol Withdrawal in Humans and Rats. *Biol Psychiatry*.
- Heyser CJ, Schulteis G, Durbin P, Koob GF, 1998 Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. *Neuropsychopharmacology* 18, 125–133. [PubMed: 9430136]
- Heyser CJ, Schulteis G, Koob GF, 1997 Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. *Alcohol Clin Exp Res* 21, 784–791. [PubMed: 9267526]
- Hirth N, Meinhardt MW, Noori HR, Salgado H, Torres-Ramirez O, Uhrig S, Broccoli L, Vengeliene V, Rossmannith M, Perreau-Lenz S, Kohr G, Sommer WH, Spanagel R, Hansson AC, 2016



- Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence. *Proc Natl Acad Sci U S A* 113, 3024–3029. [PubMed: 26903621]
- Holter SM, Engelmann M, Kirschke C, Liebsch G, Landgraf R, Spanagel R, 1998 Long-term ethanol self-administration with repeated ethanol deprivation episodes changes ethanol drinking pattern and increases anxiety-related behaviour during ethanol deprivation in rats. *Behav Pharmacol* 9, 41–48. [PubMed: 9832947]
- Holter SM, Landgraf R, Zieglgansberger W, Spanagel R, 1997 Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. *Alcohol Clin Exp Res* 21, 862–868. [PubMed: 9267536]
- Holter SM, Spanagel R, 1999 Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. *Psychopharmacology (Berl)* 145, 360–369. [PubMed: 10460312]
- Hostetler CM, Ryabinin AE, 2013 The CRF system and social behavior: a review. *Front Neurosci* 7, 92. [PubMed: 23754975]
- Hwa LS, Kalinichev M, Haddouk H, Poli S, Miczek KA, 2014 Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. *Psychopharmacology (Berl)* 231, 333–343. [PubMed: 23975038]
- Jansen JM, van Wingen G, van den Brink W, Goudriaan AE, 2015 Resting state connectivity in alcohol dependent patients and the effect of repetitive transcranial magnetic stimulation. *Eur Neuropsychopharmacol* 25, 2230–2239. [PubMed: 26481907]
- Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA, 2009 Requirement of central ghrelin signaling for alcohol reward. *Proc Natl Acad Sci U S A* 106, 11318–11323. [PubMed: 19564604]
- Jerlhag E, Landgren S, Egecioglu E, Dickson SL, Engel JA, 2011 The alcohol-induced locomotor stimulation and accumbal dopamine release is suppressed in ghrelin knockout mice. *Alcohol* 45, 341–347. [PubMed: 21145690]
- Ji D, Gilpin NW, Richardson HN, Rivier CL, Koob GF, 2008 Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. *Behav Pharmacol* 19, 1–12. [PubMed: 18195589]
- Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ, 2003 Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. *Lancet* 361, 1677–1685. [PubMed: 12767733]
- Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD, 2011 Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. *Am J Psychiatry* 168, 265–275. [PubMed: 21247998]
- Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M, 2002 Ondansetron reduces the craving of biologically predisposed alcoholics. *Psychopharmacology (Berl)* 160, 408–413. [PubMed: 11919668]
- Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J, 2000 Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. *JAMA* 284, 963–971. [PubMed: 10944641]
- Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, Topiramate for Alcoholism Advisory, B., Topiramate for Alcoholism Study, G., 2007 Topiramate for treating alcohol dependence: a randomized controlled trial. *JAMA* 298, 1641–1651. [PubMed: 17925516]
- Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC, 2014 Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. *JAMA* 311, 1889–1900. [PubMed: 24825644]
- Jupp B, Krivdic B, Krstew E, Lawrence AJ, 2011 The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. *Brain Res* 1391, 54–59. [PubMed: 21439948]
- Kallupi M, Scuppa G, de Guglielmo G, Calo G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R, 2017 Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience

to the Development of Drug Addiction. *Neuropsychopharmacology* 42, 695–706. [PubMed: 27562376]

- Kampov-Polevoy AB, Matthews DB, Gause L, Morrow AL, Overstreet DH, 2000 P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking. *Alcohol Clin Exp Res* 24, 278–284. [PubMed: 10776663]
- Kareken DA, Bragulat V, Dzmidzic M, Cox C, Talavage T, Davidson D, O'Connor SJ, 2010 Family history of alcoholism mediates the frontal response to alcoholic drink odors and alcohol in at-risk drinkers. *Neuroimage* 50, 267–276. [PubMed: 20004725]
- Kareken DA, Claus ED, Sabri M, Dzmidzic M, Kosobud AE, Radnovich AJ, Hector D, Ramchandani VA, O'Connor SJ, Lowe M, Li TK, 2004 Alcohol-related olfactory cues activate the nucleus accumbens and ventral tegmental area in high-risk drinkers: preliminary findings. *Alcohol Clin Exp Res* 28, 550–557. [PubMed: 15100605]
- Kareken DA, Grahame N, Dzmidzic M, Walker MJ, Lehigh CA, O'Connor SJ, 2012 fMRI of the brain's response to stimuli experimentally paired with alcohol intoxication. *Psychopharmacology (Berl)* 220, 787–797. [PubMed: 21993878]
- Katner SN, Magalong JG, Weiss F, 1999 Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat. *Neuropsychopharmacology* 20, 471–479. [PubMed: 10192827]
- Kaur S, Ryabinin AE, 2010 Ghrelin receptor antagonism decreases alcohol consumption and activation of periculomotor urocortin-containing neurons. *Alcohol Clin Exp Res* 34, 1525–1534. [PubMed: 20586761]
- Kehne JH, Cain CK, 2010 Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. *Pharmacol Ther* 128, 460–487. [PubMed: 20826181]
- Kendler KS, Prescott CA, Neale MC, Pedersen NL, 1997 Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. *Arch Gen Psychiatry* 54, 178–184. [PubMed: 9040286]
- Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C, 2015 Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. *J Clin Psychopharmacol* 35, 34–42. [PubMed: 25427171]
- Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C, 2007 Zonisamide decreases ethanol intake in rats and mice. *Pharmacol Biochem Behav* 87, 65–72. [PubMed: 17482246]
- Knapp DJ, Overstreet DH, Moy SS, Breese GR, 2004 SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. *Alcohol* 32, 101–111. [PubMed: 15163561]
- Koistinen M, Tuomainen P, Hyytia P, Kiiianmaa K, 2001 Naltrexone suppresses ethanol intake in 6-hydroxydopamine-treated rats. *Alcohol Clin Exp Res* 25, 1605–1612. [PubMed: 11707635]
- Koob G, Kreek MJ, 2007 Stress, dysregulation of drug reward pathways, and the transition to drug dependence. *Am J Psychiatry* 164, 1149–1159. [PubMed: 17671276]
- Koob GF, 1998 Circuits, drugs, and drug addiction. *Adv Pharmacol* 42, 978–982. [PubMed: 9328061]
- Koob GF, 2010 The role of CRF and CRF-related peptides in the dark side of addiction. *Brain Res* 1314, 3–14. [PubMed: 19912996]
- Koob GF, 2014 Neurocircuitry of alcohol addiction: synthesis from animal models. *Handb Clin Neurol* 125, 33–54. [PubMed: 25307567]
- Koob GF, Le Moal M, 1997 Drug abuse: hedonic homeostatic dysregulation. *Science* 278, 52–58. [PubMed: 9311926]
- Koob GF, Roberts AJ, Kieffer BL, Heyser CJ, Katner SN, Ciccocioppo R, Weiss F, 2003 Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. *Recent Dev Alcohol* 16, 263–281. [PubMed: 12638642]
- Koob GF, Volkow ND, 2010 Neurocircuitry of addiction. *Neuropsychopharmacology* 35, 217–238. [PubMed: 19710631]

- Kornet M, Goosen C, Van Ree JM, 1991 Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. *Psychopharmacology (Berl)* 104, 367–376. [PubMed: 1924644]
- Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C, 2003 Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. *Alcohol Clin Exp Res* 27, 1150–1155. [PubMed: 12878921]
- Krishnan-Sarin S, Wand GS, Li XW, Portoghesi PS, Froehlich JC, 1998 Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. *Pharmacol Biochem Behav* 59, 627–635. [PubMed: 9512064]
- Kuzmin A, Sandin J, Terenius L, Ogren SO, 2003 Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. *J Pharmacol Exp Ther* 304, 310–318. [PubMed: 12490606]
- Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, Rio DE, Huestis M, Anizan S, Concheiro M, Sinha R, Heilig M, 2015 The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. *Neuropsychopharmacology* 40, 1053–1063. [PubMed: 25409596]
- Landgren S, Simms JA, Hyttia P, Engel JA, Bartlett SE, Jerlhag E, 2012 Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. *Addict Biol* 17, 86–94. [PubMed: 21309944]
- Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B, 2006 The orexin system regulates alcohol-seeking in rats. *British Journal of Pharmacology* 148, 752–759. [PubMed: 16751790]
- Le AD, Quan B, Juzytch W, Fletcher PJ, Joharchi N, Shaham Y, 1998 Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. *Psychopharmacology (Berl)* 135, 169–174. [PubMed: 9497022]
- Le Magnen J, Tran G, Durlach J, Martin C, 1987 Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. *Alcohol* 4, 97–102. [PubMed: 3580139]
- Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA, 2014 Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. *Biol Psychiatry* 76, 734–741. [PubMed: 24775991]
- Lei K, Wegner SA, Yu JH, Mototake A, Hu B, Hopf FW, 2016 Nucleus Accumbens Shell and mPFC but Not Insula Orexin-1 Receptors Promote Excessive Alcohol Drinking. *Front Neurosci* 10, 400. [PubMed: 27625592]
- Liang JH, Chen F, Krstew E, Cowen MS, Carroll FY, Crawford D, Beart PM, Lawrence AJ, 2006 The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. *Neuropharmacology* 50, 632–639. [PubMed: 16406445]
- Lido HH, Marston H, Ericson M, Soderpalm B, 2012 The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. *Addict Biol* 17, 897–907. [PubMed: 21955180]
- Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R, Group NS, 2013 A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. *J Addict Med* 7, 277–286. [PubMed: 23728065]
- Liu X, Weiss F, 2002a Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. *J Neurosci* 22, 7856–7861. [PubMed: 12223538]
- Liu X, Weiss F, 2002b Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. *J Pharmacol Exp Ther* 300, 882–889. [PubMed: 11861794]
- Logrip ML, Vendruscolo LF, Schlosburg JE, Koob GF, Zorrilla EP, 2014 Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. *Neuropsychopharmacology* 39, 1722–1731. [PubMed: 24549104]

- Loi B, Maccioni P, Lobina C, Carai MA, Gessa GL, Thomas AW, Malherbe P, Colombo G, 2013 Reduction of alcohol intake by the positive allosteric modulator of the GABA(B) receptor, rac-BHFF, in alcohol-preferring rats. *Alcohol* 47, 69–73. [PubMed: 23218664]
- Maccioni P, Colombo G, Lorrain I, Fara F, Carai MAM, Gessa GL, Brizzi A, Mugnaini C, Corelli F, 2019 Anti-addictive properties of COR659 - Additional pharmacological evidence and comparison with a series of novel analogues. *Alcohol* 75, 55–66. [PubMed: 30445248]
- Maccioni P, Orru A, Korkosz A, Gessa GL, Carai MA, Colombo G, Bienkowski P, 2007 Cue-induced reinstatement of ethanol seeking in Sardinian alcohol-preferring rats. *Alcohol* 41, 31–39. [PubMed: 17452297]
- Maccioni P, Thomas AW, Carai MA, Gessa GL, Malherbe P, Colombo G, 2010 The positive allosteric modulator of the GABA(B) receptor, rac-BHFF, suppresses alcohol self-administration. *Drug Alcohol Depend* 109, 96–103. [PubMed: 20089372]
- Maccioni P, Zaru A, Loi B, Lobina C, Carai MA, Gessa GL, Capra A, Mugnaini C, Pasquini S, Corelli F, Hyttia P, Lumeng L, Colombo G, 2012 Comparison of the effect of the GABA(B) receptor agonist, baclofen, and the positive allosteric modulator of the GABA(B) receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. *Alcohol Clin Exp Res* 36, 1748–1766. [PubMed: 22486245]
- Majchrowicz E, 1975 Induction of physical dependence upon ethanol and the associated behavioral changes in rats. *Psychopharmacologia* 43, 245–254. [PubMed: 1237914]
- Mann K, Bladstrom A, Torup L, Gual A, van den Brink W, 2013 Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. *Biol Psychiatry* 73, 706–713. [PubMed: 23237314]
- Mann K, Kiefer F, Spanagel R, Littleton J, 2008 Acamprosate: recent findings and future research directions. *Alcohol Clin Exp Res* 32, 1105–1110. [PubMed: 18540918]
- Martin-Fardon R, Ciccocioppo R, Massi M, Weiss F, 2000 Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. *Neuroreport* 11, 1939–1943. [PubMed: 10884047]
- Martin-Fardon R, Weiss F, 2014 N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking. *Addict Biol* 19, 233–236. [PubMed: 22830647]
- Martin-Fardon R, Zorrilla EP, Ciccocioppo R, Weiss F, 2010 Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. *Brain Res* 1314, 145–161. [PubMed: 20026088]
- Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M, 2004 Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. *Neuropsychopharmacology* 29, 1190–1202. [PubMed: 15010698]
- Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M, 2007 Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. *Am J Psychiatry* 164, 622–629. [PubMed: 17403976]
- Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A, 2014 Gabapentin treatment for alcohol dependence: a randomized clinical trial. *JAMA Intern Med* 174, 70–77. [PubMed: 24190578]
- Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E, 1994 A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. *Alcohol Clin Exp Res* 18, 1162–1167. [PubMed: 7847600]
- Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB, 1999 A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. *Arch Gen Psychiatry* 56, 719–724. [PubMed: 10435606]
- McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetraault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E, 2009 Varenicline reduces alcohol self-administration in heavy-drinking smokers. *Biol Psychiatry* 66, 185–190. [PubMed: 19249750]
- McKinney WT Jr., Bunney WE Jr., 1969 Animal model of depression. I. Review of evidence: implications for research. *Arch Gen Psychiatry* 21, 240–248. [PubMed: 4980592]

- McKinzie DL, Nowak KL, Yorger L, McBride WJ, Murphy JM, Lumeng L, Li TK, 1998 The alcohol deprivation effect in the alcohol-preferring P rat under free-drinking and operant access conditions. *Alcohol Clin Exp Res* 22, 1170–1176. [PubMed: 9726292]
- McLellan AT, Lewis DC, O'Brien CP, Kleber HD, 2000 Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. *JAMA* 284, 1689–1695. [PubMed: 11015800]
- Mechtcheriakov S, Brenneis C, Egger K, Koppelstaetter F, Schocke M, Marksteiner J, 2007 A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. *J Neurol Neurosurg Psychiatry* 78, 610–614. [PubMed: 17088334]
- Mendelson JH, Ladou J, 1964 [Experimentally Induced Chronic Alcoholic Intoxication and Its Suspension. I. Psychotoxicologic Results]. *Hippokrates* 35, 245–252. [PubMed: 14225149]
- Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F, 1995 Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. *J Neurosci* 15, 5439–5447. [PubMed: 7643193]
- Miller WR, Leckman AL, Delaney HD, Tinkcom M, 1992 Long-term follow-up of behavioral self-control training. *J Stud Alcohol* 53, 249–261. [PubMed: 1583904]
- Monti PM, Rohsenow DJ, Hutchison KE, 2000 Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. *Addiction* 95 Suppl 2, S229–236. [PubMed: 11002917]
- Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB, 1999 Naltrexone's effect on cue-elicited craving among alcoholics in treatment. *Alcohol Clin Exp Res* 23, 1386–1394. [PubMed: 10470982]
- Moorman DE, James MH, Kilroy EA, Aston-Jones G, 2017 Orexin/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats. *Brain Res* 1654, 34–42. [PubMed: 27771284]
- Muller CA, Geisel O, Pelz P, Higl V, Kruger J, Stickel A, Beck A, Wernecke KD, Hellweg R, Heinz A, 2015 High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. *European Neuropsychopharmacology* 25, 1167–1177. [PubMed: 26048580]
- Muller-Oehring EM, Jung YC, Pfefferbaum A, Sullivan EV, Schulte T, 2015 The Resting Brain of Alcoholics. *Cereb Cortex* 25, 4155–4168. [PubMed: 24935777]
- Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL, 2009 A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. *Alcoholism, Clinical and Experimental Research* 33, 1582–1588.
- Natividad LA, Buczynski MW, Herman MA, Kirson D, Oleata CS, Irimia C, Polis I, Ciccocioppo R, Roberto M, Parsons LH, 2017 Constitutive Increases in Amygdalar Corticotropin-Releasing Factor and Fatty Acid Amide Hydrolase Drive an Anxious Phenotype. *Biol Psychiatry* 82, 500–510. [PubMed: 28209423]
- Newport DJ, Stowe ZN, Nemeroff CB, 2002 Parental depression: animal models of an adverse life event. *Am J Psychiatry* 159, 1265–1283. [PubMed: 12153816]
- Nguyen SA, Malcolm R, Middaugh LD, 2007 Topiramate reduces ethanol consumption by C57BL/6 mice. *Synapse* 61, 150–156. [PubMed: 17146766]
- Nielsen DM, 2006 Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? *Life Sci* 78, 909–919. [PubMed: 16122764]
- Nunes EV, Levin FR, 2004 Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. *JAMA* 291, 1887–1896. [PubMed: 15100209]
- O'Brien CP, Childress AR, Ehrman R, Robbins SJ, 1998 Conditioning factors in drug abuse: Can they explain compulsion? *J Psychopharmacol* 12, 15–22. [PubMed: 9584964]
- O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B, 1992 Naltrexone and coping skills therapy for alcohol dependence. A controlled study. *Arch Gen Psychiatry* 49, 881–887. [PubMed: 1444726]

- Olive MF, Koenig HN, Nannini MA, Hodge CW, 2002a Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. *Pharmacol Biochem Behav* 72, 213–220. [PubMed: 11900791]
- Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW, 2002b Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. *Eur J Pharmacol* 437, 55–61. [PubMed: 11864639]
- Olney JJ, Navarro M, Thiele TE, 2017 The Role of Orexin Signaling in the Ventral Tegmental Area and Central Amygdala in Modulating Binge-Like Ethanol Drinking Behavior. *Alcohol Clin Exp Res* 41, 551–561. [PubMed: 28097729]
- Orru A, Lai P, Lobina C, Maccioni P, Piras P, Scanu L, Froestl W, Gessa GL, Carai MA, Colombo G, 2005 Reducing effect of the positive allosteric modulators of the GABA(B) receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. *Eur J Pharmacol* 525, 105–111. [PubMed: 16289452]
- Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP, 2003 A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. *Neuropsychopharmacology* 28, 1546–1552. [PubMed: 12813472]
- Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M, 2015 Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. *JAMA Psychiatry* 72, 430–437. [PubMed: 25760804]
- Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P, 1995 Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. *Alcohol Alcohol* 30, 239–247. [PubMed: 7662044]
- Park PE, Schlosburg JE, Vendruscolo LF, Schulteis G, Edwards S, Koob GF, 2015 Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. *Addict Biol* 20, 275–284. [PubMed: 24330252]
- Penland S, Hoplight B, Obernier J, Crews FT, 2001 Effects of nicotine on ethanol dependence and brain damage. *Alcohol* 24, 45–54. [PubMed: 11524181]
- Perfumi M, Mattioli L, Cucculelli M, Massi M, 2005 Reduction of ethanol intake by chronic treatment with *Hypericum perforatum*, alone or combined with naltrexone in rats. *J Psychopharmacol* 19, 448–454. [PubMed: 16166181]
- Pfefferbaum A, Sullivan EV, Mathalon DH, Shear PK, Rosenbloom MJ, Lim KO, 1995 Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. *Alcohol Clin Exp Res* 19, 1177–1191. [PubMed: 8561288]
- Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O'Malley SS, Wong CJ, 2016 Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. *Alcohol Clin Exp Res* 40, 1935–1944. [PubMed: 27435979]
- Prescott CA, Kendler KS, 1999 Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. *Am J Psychiatry* 156, 34–40. [PubMed: 9892295]
- Primus RJ, Yevich E, Baltazar C, Gallager DW, 1997 Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. *Neuropsychopharmacology* 17, 308–316. [PubMed: 9348546]
- Rando K, Hong KI, Bhagwagar Z, Li CS, Bergquist K, Guarnaccia J, Sinha R, 2011 Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. *Am J Psychiatry* 168, 183–192. [PubMed: 21078704]
- Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED, 2014 Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. *Psychopharmacology (Berl)* 231, 3843–3853. [PubMed: 24733235]
- Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A, Bartlett SE, 2008 Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. *Psychopharmacology (Berl)* 199, 109–117. [PubMed: 18470506]

- Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, Janda KD, Zorrilla EP, Koob GF, 2008 MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. *Pharmacol Biochem Behav* 88, 497–510. [PubMed: 18031798]
- Rimondini R, Arlinde C, Sommer W, Heilig M, 2002 Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. *FASEB J* 16, 27–35. [PubMed: 11772933]
- Rimondini R, Sommer WH, Dall'Olio R, Heilig M, 2008 Long-lasting tolerance to alcohol following a history of dependence. *Addict Biol* 13, 26–30. [PubMed: 17850416]
- Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, Cottone P, Madamba SG, Stouffer DG, Zorrilla EP, Koob GF, Siggins GR, Parsons LH, 2010 Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. *Biol Psychiatry* 67, 831–839. [PubMed: 20060104]
- Roberto M, Gilpin NW, O'Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF, 2008 Cellular and behavioral interactions of gabapentin with alcohol dependence. *J Neurosci* 28, 5762–5771. [PubMed: 18509038]
- Rodd-Henricks ZA, McKinzie DL, Shaikh SR, Murphy JM, McBride WJ, Lumeng L, Li TK, 2000 Alcohol deprivation effect is prolonged in the alcohol preferring (P) rat after repeated deprivations. *Alcohol Clin Exp Res* 24, 8–16. [PubMed: 10656186]
- Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F, 1997 Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. *Science* 276, 2050–2054. [PubMed: 9197270]
- Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB, 2000 Naltrexone's effects on reactivity to alcohol cues among alcoholic men. *J Abnorm Psychol* 109, 738–742. [PubMed: 11195999]
- Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jimenez A, Benito A, Pedregal C, Weiss F, Statnick MA, 2016 A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. *Alcohol Clin Exp Res* 40, 945–954. [PubMed: 27084498]
- Rosenberg H, 1993 Prediction of controlled drinking by alcoholics and problem drinkers. *Psychol Bull* 113, 129–139. [PubMed: 8426872]
- Ruggeri B, Braconi S, Cannella N, Kallupi M, Soverchia L, Ciccocioppo R, Ubaldi M, 2010 Neuropeptide S receptor gene expression in alcohol withdrawal and protracted abstinence in postdependent rats. *Alcoholism, Clinical and Experimental Research* 34, 90–97.
- Sabino V, Cottone P, Koob GF, Steardo L, Lee MJ, Rice KC, Zorrilla EP, 2006 Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. *Psychopharmacology (Berl)* 189, 175–186. [PubMed: 17047935]
- Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD, 2010 National and State Costs of Excessive Alcohol Consumption. *Am J Prev Med* 49, e73–e79. [PubMed: 26477807]
- Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M, 1998 Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92, 573–585. [PubMed: 9491897]
- Sanchez MM, Young LJ, Plotsky PM, Insel TR, 1999 Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. *J Comp Neurol* 408, 365–377. [PubMed: 10340512]
- Santucci AC, Cortes C, Bettica A, Cortes F, 2008 Chronic ethanol consumption in rats produces residual increases in anxiety 4 months after withdrawal. *Behav Brain Res* 188, 24–31. [PubMed: 18061285]
- Sass H, Soyka M, Mann K, Ziegler-Winkel W, 1996 Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. *Archives of General Psychiatry* 53, 673–680. [PubMed: 8694680]

- Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H, 2014 Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. *Psychopharmacology (Berl)* 231, 3799–3807. [PubMed: 24647921]
- Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H, 2013 Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. *Neuropsychopharmacology* 38, 414–422. [PubMed: 23032071]
- Schacht JP, Voronin KE, Randall PK, Anton RF, 2018 Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. *Neuropsychopharmacology* 43, 1247–1256. [PubMed: 29362512]
- Schank JR, Pickens CL, Rowe KE, Cheng K, Thorsell A, Rice KC, Shaham Y, Heilig M, 2011 Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. *Psychopharmacology (Berl)* 218, 111–119. [PubMed: 21340476]
- Schulz D, Southekal S, Junnarkar SS, Pratte JF, Purschke ML, Stoll SP, Ravindranath B, Maramraju SH, Krishnamoorthy S, Henn FA, O'Connor P, Woody CL, Schlyer DJ, Vaska P, 2011 Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph. *Nat Methods* 8, 347–352. [PubMed: 21399637]
- Schulz D, Vaska P, 2011 Integrating PET with behavioral neuroscience using RatCAP tomography. *Rev Neurosci* 22, 647–655. [PubMed: 22098449]
- Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, Grigoriadis DE, Pich EM, Leggio L, Heilig M, 2016 The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. *Neuropsychopharmacology* 41, 2818–2829. [PubMed: 27109623]
- Senatorov VV, Damadzic R, Mann CL, Schwandt ML, George DT, Hommer DW, Heilig M, Momenan R, 2015 Reduced anterior insula, enlarged amygdala in alcoholism and associated depleted von Economo neurons. *Brain* 138, 69–79. [PubMed: 25367022]
- Sidhpura N, Weiss F, Martin-Fardon R, 2010 Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence. *Biol Psychiatry* 67, 804–811. [PubMed: 20189165]
- Sigvardsson S, Bohman M, Cloninger CR, 1996 Replication of the Stockholm Adoption Study of alcoholism. Confirmatory cross-fostering analysis. *Arch Gen Psychiatry* 53, 681–687. [PubMed: 8694681]
- Sinclair JD, Li TK, 1989 Long and short alcohol deprivation: effects on AA and P alcohol-preferring rats. *Alcohol* 6, 505–509. [PubMed: 2597353]
- Sinclair JD, Senter RJ, 1968 Development of an alcohol-deprivation effect in rats. *Q J Stud Alcohol* 29, 863–867. [PubMed: 5705408]
- Sinha R, 2001 How does stress increase risk of drug abuse and relapse? *Psychopharmacology (Berl)* 158, 343–359. [PubMed: 11797055]
- Sinha R, 2011 Modeling Relapse Situations in the Human Laboratory. *Curr Top Behav Neurosci*.
- Sinha R, 2013 Modeling relapse situations in the human laboratory. *Curr Top Behav Neurosci* 13, 379–402. [PubMed: 21769721]
- Sinha R, Fox HC, Hong KA, Bergquist K, Bhagwagar Z, Siedlarz KM, 2009 Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. *Neuropsychopharmacology* 34, 1198–1208. [PubMed: 18563062]
- Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ, 2011 Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. *Arch Gen Psychiatry* 68, 942–952. [PubMed: 21536969]
- Sinha R, Li CSR, 2007 Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. *Drug and Alcohol Review* 26, 25–31. [PubMed: 17364833]
- Sinha R, O'Malley SS, 1999 Craving for alcohol: findings from the clinic and the laboratory. *Alcohol* 34, 223–230. [PubMed: 10344782]
- Skelton KH, Oren D, Gutman DA, Easterling K, Holtzman SG, Nemeroff CB, Owens MJ, 2007 The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. *Eur J Pharmacol* 571, 17–24. [PubMed: 17610870]



- Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS, Heilig MA, 2008 Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala *crhr1* expression following a history of dependence. *Biol Psychiatry* 63, 139–145. [PubMed: 17585886]
- Soyka M, Muller CA, 2017 Pharmacotherapy of alcoholism - an update on approved and off-label medications. *Expert Opin Pharmacother* 18, 1187–1199. [PubMed: 28658981]
- Spanagel R, Holter SM, 2000 Pharmacological validation of a new animal model of alcoholism. *J Neural Transm (Vienna)* 107, 669–680. [PubMed: 10943907]
- Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F, 2014 Acamprosate produces its anti-relapse effects via calcium. *Neuropsychopharmacology* 39, 783–791. [PubMed: 24081303]
- Steenland P, Simms JA, Holgate J, Richards JK, Bartlett SE, 2007 Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. *Proc Natl Acad Sci U S A* 104, 12518–12523. [PubMed: 17626178]
- Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M, Ruggeri B, Heilig M, Demopulos G, Gaitanaris G, Massi M, Ciccocioppo R, 2011 Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. *Biological Psychiatry* 69, 642–649. [PubMed: 21276964]
- Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'Brien CP, 1998 A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. *Alcohol* 15, 281–289. [PubMed: 9590512]
- Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, 2001 Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. *Alcohol* 23, 109–116. [PubMed: 11331108]
- Suchankova P, Steenland P, Fredriksson I, Engel JA, Jerlhag E, 2013 Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. *PLoS One* 8, e71284. [PubMed: 23977009]
- Suh JJ, Pettinati HM, Kampman KM, O'Brien CP, 2006 The status of disulfiram: a half of a century later. *J Clin Psychopharmacol* 26, 290–302. [PubMed: 16702894]
- Terracciano A, Lockenhoff CE, Crum RM, Bienvenu OJ, Costa PT Jr., 2008 Five-Factor Model personality profiles of drug users. *BMC Psychiatry* 8, 22. [PubMed: 18405382]
- Thomas SE, Bacon AK, Randall PK, Brady KT, See RE, 2011 An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics. *Psychopharmacology (Berl)* 218, 19–28. [PubMed: 21274703]
- Thompson A, Owens L, Richardson P, Pirmohamed M, 2017 Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. *Eur Neuropsychopharmacol* 27, 1077–1089. [PubMed: 28939163]
- Thorsell A, Schank JR, Singley E, Hunt SP, Heilig M, 2010 Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. *Psychopharmacology (Berl)* 209, 103–111. [PubMed: 20112009]
- Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M, Saam C, Lascorz J, Soyka M, Preuss UW, Rujescu D, Skowronek MH, Rietschel M, Spanagel R, Heinz A, Laucht M, Mann K, Schumann G, 2006 Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. *Mol Psychiatry* 11, 594–602. [PubMed: 16550213]
- Tucci S, Cheeta S, Seth P, File SE, 2003 Corticotropin releasing factor antagonist, alpha-helical CRF(9–41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. *Psychopharmacology (Berl)* 167, 251–256. [PubMed: 12669178]
- Ubaldi M, Cannella N, Ciccocioppo R, 2016a Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. *Prog Brain Res* 224, 251–284. [PubMed: 26822362]
- Ubaldi M, Giordano A, Severi I, Li H, Kallupi M, de Guglielmo G, Ruggeri B, Stopponi S, Ciccocioppo R, Cannella N, 2016b Activation of Hypocretin-1/Orexin-A Neurons Projecting to the Bed Nucleus of the Stria Terminalis and Paraventricular Nucleus Is Critical for Reinstatement of Alcohol Seeking by Neuropeptide S. *Biol Psychiatry* 79, 452–462. [PubMed: 26055195]

- Vallender EJ, Ruedi-Bettschen D, Miller GM, Platt DM, 2010 A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. *Drug Alcohol Depend* 109, 252–256. [PubMed: 20153935]
- Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE, 2000 Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. *J Comp Neurol* 428, 191–212. [PubMed: 11064361]
- Vengeliene V, Bilbao A, Spanagel R, 2014 The alcohol deprivation effect model for studying relapse behavior: a comparison between rats and mice. *Alcohol* 48, 313–320. [PubMed: 24811155]
- Vengeliene V, Leonardi-Essmann F, Sommer WH, Marston HM, Spanagel R, 2010 Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. *Biol Psychiatry* 68, 704–711. [PubMed: 20655511]
- Vengeliene V, Siegmund S, Singer MV, Sinclair JD, Li TK, Spanagel R, 2003 A comparative study on alcohol-preferring rat lines: effects of deprivation and stress phases on voluntary alcohol intake. *Alcohol Clin Exp Res* 27, 1048–1054. [PubMed: 12878910]
- Vengeliene V, Takahashi TT, Dravolina OA, Belozertseva I, Zvartau E, Bernalov AY, Spanagel R, 2018 Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. *Psychopharmacology (Berl)* 235, 1955–1965. [PubMed: 29651507]
- Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Burr G, Pascani K, Dewey SL, Wolf AP, 1992 Decreased brain metabolism in neurologically intact healthy alcoholics. *Am J Psychiatry* 149, 1016–1022. [PubMed: 1636801]
- Volkow ND, Wang GJ, Hitzemann R, Fowler JS, Overall JE, Burr G, Wolf AP, 1994 Recovery of brain glucose metabolism in detoxified alcoholics. *Am J Psychiatry* 151, 178–183. [PubMed: 8296885]
- Volkow ND, Wang GJ, Overall JE, Hitzemann R, Fowler JS, Pappas N, Frecska E, Piscani K, 1997 Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. *Alcohol Clin Exp Res* 21, 1278–1284. [PubMed: 9347090]
- Vollstadt-Klein S, Wichert S, Rabinstein J, Buhler M, Klein O, Ende G, Hermann D, Mann K, 2010 Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. *Addiction* 105, 1741–1749. [PubMed: 20670348]
- Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP, 1992a Naltrexone in the treatment of alcohol dependence. *Archives of General Psychiatry* 49, 876–880. [PubMed: 1345133]
- Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP, 1992b Naltrexone in the treatment of alcohol dependence. *Archives of General Psychiatry* 49, 876–880. [PubMed: 1345133]
- Walitzer KS, Connors GJ, 1999 Treating problem drinking. *Alcohol Res Health* 23, 138–143. [PubMed: 10890808]
- Waller MB, McBride WJ, Lumeng L, Li TK, 1982 Induction of dependence on ethanol by free-choice drinking in alcohol-preferring rats. *Pharmacol Biochem Behav* 16, 501–507. [PubMed: 7200611]
- Wang GJ, Volkow ND, Franceschi D, Fowler JS, Thanos PK, Scherbaum N, Pappas N, Wong CT, Hitzemann RJ, Felder CA, 2000 Regional brain metabolism during alcohol intoxication. *Alcohol Clin Exp Res* 24, 822–829. [PubMed: 10888070]
- Watson WP, Robinson E, Little HJ, 1997 The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. *Neuropharmacology* 36, 1369–1375. [PubMed: 9423924]
- Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF, Frost JJ, Wong DF, Wand GS, 2013 Influence of OPRM1 Asn40Asp variant (A118G) on [<sup>11</sup>C]carfentanil binding potential: preliminary findings in human subjects. *Int J Neuropsychopharmacol* 16, 47–53. [PubMed: 22397905]
- Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR, 2001 Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. *Ann N Y Acad Sci* 937, 1–26. [PubMed: 11458532]
- Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, Zhang HT, Liang JH, 2012 The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. *Alcohol Clin Exp Res* 36, 2157–2167. [PubMed: 22671516]

- Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T, 2013 Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 382, 1575–1586. [PubMed: 23993280]
- Willner P, 1984 The validity of animal models of depression. *Psychopharmacology* 83, 1–16. [PubMed: 6429692]
- Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R, 2014 The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. *Pharmacol Ther* 141, 283–299. [PubMed: 24189487]
- Zakiniacz Y, Scheinost D, Seo D, Sinha R, Constable RT, 2017 Cingulate cortex functional connectivity predicts future relapse in alcohol dependent individuals. *Neuroimage Clin* 13, 181–187. [PubMed: 27981033]
- Zhu X, Cortes CR, Mathur K, Tomasi D, Momenan R, 2017 Model-free functional connectivity and impulsivity correlates of alcohol dependence: a resting-state study. *Addict Biol* 22, 206–217. [PubMed: 26040546]
- Zhu X, Dutta N, Helton SG, Schwandt M, Yan J, Hodgkinson CA, Cortes CR, Kerich M, Hall S, Sun H, Phillips M, Momenan R, Lohoff FW, 2015 Resting-state functional connectivity and presynaptic monoamine signaling in Alcohol Dependence. *Hum Brain Mapp* 36, 4808–4818. [PubMed: 26368063]
- Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, Sarai BK, Maltby K, Fernando D, Warren L, Hosking LK, Waterworth D, Korzeniowska A, Win B, Richards DB, Vasist Johnson L, Fletcher PC, Bullmore ET, 2016 Opioid Antagonists and the A118G Polymorphism in the mu-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. *Neuropsychopharmacology* 41, 2647–2657. [PubMed: 27109624]
- Zimmermann US, O'Connor S, Ramchandani VA, 2013 Modeling alcohol self-administration in the human laboratory. *Curr Top Behav Neurosci* 13, 315–353. [PubMed: 21792747]
- Ziolkowski M, Czarnecki D, Budzynski J, Rosinska Z, Zekanowska E, Goralczyk B, 2016 Orexin in Patients with Alcohol Dependence Treated for Relapse Prevention: A Pilot Study. *Alcohol Alcohol* 51, 416–421. [PubMed: 26597795]
- Zorrilla EP, Koob GF, 2004 The therapeutic potential of CRF1 antagonists for anxiety. *Expert Opin Investig Drugs* 13, 799–828.
- Zorrilla EP, Logrip ML, Koob GF, 2014 Corticotropin releasing factor: a key role in the neurobiology of addiction. *Front Neuroendocrinol* 35, 234–244. [PubMed: 24456850]
- Zorrilla EP, Valdez GR, Weiss F, 2001 Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. *Psychopharmacology (Berl)* 158, 374–381. [PubMed: 11797058]
- Zuckerman M, 1986 Sensation seeking and the endogenous deficit theory of drug abuse. *NIDA Res Monogr* 74, 59–70. [PubMed: 3122054]

**Table 1:**

New drug Targets of potential interest in AUD.

Target	Drug	Drug Activity	Key Finding	Reference
PPAR $\gamma$	<ul style="list-style-type: none"> <li>• Pioglitazone</li> </ul>	Agonism	<ul style="list-style-type: none"> <li>• Reduce SA</li> <li>• Reduce stress-induced reinstatement</li> </ul>	(Stopponi et al., 2011)
PPAR $\alpha$	<ul style="list-style-type: none"> <li>• Fenofibrate</li> <li>• Tesaglitazar</li> <li>• Bezafibrate</li> </ul>	Agonism	<ul style="list-style-type: none"> <li>• Reduce SA</li> </ul>	(Blednov et al., 2015)
PDE4	<ul style="list-style-type: none"> <li>• Rolipram</li> </ul>	Inhibition	<ul style="list-style-type: none"> <li>• Reduce SA</li> </ul>	(Wen et al., 2012)
PDE10	<ul style="list-style-type: none"> <li>• TP-10</li> </ul>	Inhibition	<ul style="list-style-type: none"> <li>• Reduce SA</li> </ul>	(Logrip et al., 2014)
CRF1R	<ul style="list-style-type: none"> <li>• CRA1000</li> <li>• MTIP</li> <li>• MPZP</li> <li>• LWH-63</li> <li>• Antalarmin</li> <li>• KO mice</li> <li>• D-Phe-CRF(12–41)</li> </ul>	Antagonism	<ul style="list-style-type: none"> <li>• Reduce SA</li> <li>• Reduce withdrawal</li> </ul>	(Chu et al., 2007; Funk et al., 2007; Gehlert et al., 2007; Gilpin et al., 2008; Knapp et al., 2004; Richardson et al., 2008; Sabino et al., 2006; Sommer et al., 2008)
NOP	<ul style="list-style-type: none"> <li>• N/OFQ</li> <li>• Ro 64–6198</li> <li>• LY2940094</li> <li>• KO rats</li> </ul>	Agonism Antagonism	<ul style="list-style-type: none"> <li>• Reduce CPP</li> <li>• Reduce SA</li> <li>• Reduce withdrawal</li> </ul>	(Ciccocioppo et al., 2004; Ciccocioppo et al., 1999; Economidou et al., 2011; Kallupi et al., 2017; Kuzmin et al., 2003; Martin-Fardon et al., 2000; Rorick-Kehn et al., 2016)
OX1	<ul style="list-style-type: none"> <li>• SB-334867</li> </ul>		<ul style="list-style-type: none"> <li>• Reduce cue- and stress-induced reinstatement</li> </ul>	(Lawrence et al., 2006; Richards et al., 2008)
NPSR	<ul style="list-style-type: none"> <li>• NPS</li> </ul>	Agonism	<ul style="list-style-type: none"> <li>• Increase cue-induced reinstatement</li> <li>• Reduce SA in alcohol-preferring rats</li> </ul>	(Cannella et al., 2009; Cannella et al., 2016; Ruggeri et al., 2010)
NK1R	<ul style="list-style-type: none"> <li>• LY686017</li> <li>• L822429</li> <li>• KO mice</li> </ul>	Antagonism	<ul style="list-style-type: none"> <li>• Reduce SA</li> <li>• Reduce CPP</li> <li>• Reduce stress-induced reinstatement</li> </ul>	(Ayanwuyi et al., 2015; George et al., 2008; Schank et al., 2011; Thorsell et al., 2010)
mAChR subtype 5	<ul style="list-style-type: none"> <li>• ML375</li> </ul>	NAM	<ul style="list-style-type: none"> <li>• Reduce SA</li> <li>• Reduce cue-induced reinstatement</li> </ul>	(Berizzi et al., 2018)

SA= Self Administration; CPP=Conditioned Place Preference; NAM= Negative Allosteric Modulator.

**Table 2:**

Medications approved (\*) or under clinical investigation for AUD.

Drug	Molecular Target	Efficacy in AUD	Key References	Approved
Topiramate	<ul style="list-style-type: none"> <li>Kainate/AMPA receptors</li> <li>GABA<sub>A</sub></li> <li>Carbonic anhydrase</li> <li>Sodium and calcium channels</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue drinking</li> <li>Prevent relapse</li> </ul>	(Johnson et al., 2003; Johnson et al., 2007)	
Gabapentin	<ul style="list-style-type: none"> <li>Calcium channels</li> <li>GABA<sub>B</sub></li> </ul>	<ul style="list-style-type: none"> <li>Increase abstinence</li> <li>Reduce drinking</li> </ul>	(Mason et al., 2014; Myrick et al., 2009)	
*Nalmefene	<ul style="list-style-type: none"> <li>Opioid Receptors</li> </ul>	<ul style="list-style-type: none"> <li>Reduce drinking</li> </ul>	(Gual et al., 2013; Mann et al., 2013; Mason et al., 1994; Mason et al., 1999)	EMA
*Naltrexone	<ul style="list-style-type: none"> <li>Opioid Receptors</li> </ul>	<ul style="list-style-type: none"> <li>Increase abstinence</li> <li>Reduce drinking</li> </ul>	(Bouza et al., 2004; O'Malley et al., 1992; Volpicelli et al., 1992b)	FDA and EMA
GHB (Gamma Hydroxy Butyrate also know as Sodium Oxybate)	<ul style="list-style-type: none"> <li>GABA<sub>A</sub></li> <li>GABA<sub>B</sub></li> </ul>	<ul style="list-style-type: none"> <li>Reduce craving</li> <li>Increase abstinence</li> </ul>	(Addolorato et al., 1996)	Italy and Austria
*Baclofen	<ul style="list-style-type: none"> <li>GABA<sub>B</sub></li> </ul>	<ul style="list-style-type: none"> <li>Reduce drinking</li> <li>Increase abstinence</li> </ul>	(Addolorato et al., 2002; Muller et al., 2015)	France
Ondansetron	<ul style="list-style-type: none"> <li>5-HT<sub>3</sub></li> </ul>	<ul style="list-style-type: none"> <li>Early onset AUD</li> </ul>	(Johnson et al., 2002; Johnson et al., 2000)	
Varenicline	<ul style="list-style-type: none"> <li>Acetylcholine Receptors</li> </ul>	<ul style="list-style-type: none"> <li>Reduce drinking</li> </ul>	(Litten et al., 2013; McKee et al., 2009)	
Zonisamide	<ul style="list-style-type: none"> <li>Sodium channels</li> </ul>	<ul style="list-style-type: none"> <li>Reduce drinking</li> </ul>	(Arias et al., 2010; Knapp et al., 2015)	
*Acamprosate	<ul style="list-style-type: none"> <li>mGluR5?</li> <li>Ca<sup>++</sup>?</li> </ul>	<ul style="list-style-type: none"> <li>Increase abstinence</li> </ul>	(Paille et al., 1995; Sass et al., 1996)	FDA and EMA
*Disulfiram	<ul style="list-style-type: none"> <li>Aldehyde dehydrogenase</li> </ul>	<ul style="list-style-type: none"> <li>Reduce drinking</li> </ul>	(Suh et al., 2006)	FDA and EMA